Study ID: [REMOVED]   
Document Date: Clinical Study Protocol Version 5: 08 Dec 2022Official Title: A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome 
Induced by Immune Effector Cell Therapy
,QF\WH&RUSRUDWLRQ  3DJHRI
3URWRFRO,1&% $P 9HUVLRQ '(&
99&/,1 &21),'(17,$/ 7,7/(3$*( 
&OLQLFDO6WXG\3URWRFRO 
,1&% 
$3KDVH 6WXG\RI,WDFLWLQLEIRUWKH3UHYHQWLRQRI&\WRNLQH5HOHDVH
6\QGURPH,QGXFHGE\,PPXQH(IIHFWRU&HOO7KHUDS\ 
3URGXFW ,WDFLWLQLE,1&%
,1'1XPEHU 
3KDVHRI6WXG\ 
6SRQVRU ,QF\WH&RUSRUDWLRQ
$XJXVWLQH&XW 2II
:LOPLQJWRQ'(
2ULJLQDO3URWRFRO -8/
3URWRFRO$PHQGPHQW $35
3URWRFRO$PHQGPHQW 2&7
3URWRFRO$PHQGPHQW $8*
3URWRFRO$PHQGPHQW '(&
7KLVVWXG\ZLOOEHSHUIRUPHGLQDFFRUGDQFHZLWKHWKLFDOSULQFLS OHVWKDWKDYHWKHLURULJLQLQWKH'HFODUDWLRQRI
+HOVLQNL%UD]LODQGFRQGXFWHGLQDGKHUHQFHWRWKHVWXG\ 3URWRFRODSSOLFDEOH*RRG &OLQLFDO3UDFWLFHVDQG
DSSOLFDEOHODZVDQGFRXQWU\ VSHFLILFUHJXODWLRQVLQFOXGLQJ:020HGLFDO5HVHDUFK,QYROYLQJ +XPDQ3DUWLFLSDQWV
$FWDQG&OLQLFDO7ULDOV5HJXODWLR Q(81RLQZKLFK WKHVWXG\LVEHLQJFRQGXFWHG 
7KHLQIRUPDWLRQLQWKLVGRF XPHQWLVFRQILGHQWLDO1RSDUWRIWKLVLQIRUPDWLRQPD\EHGXSOL FDWHGUHIHUHQFHGRU
WUDQVPLWWHGLQDQ\IRUPRUE\DQ \PHDQVHOHFWUR QLFPHFKDQLFDO SKRWRFRS\UHFRUGLQJRURWKHUZLVHZLWKRXWSULRU
ZULWWHQFRQVHQW 
PPD
Incyte Corporation  Page 2 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046 CONFIDENTIAL  INVESTIGATOR'S  AGREEMENT  
I have read th e INCB 39110 -211 Protocol  Amendment 4 (dated 08 DEC  2022 ) and agree to 
conduct the study as outlined .  I agree to maintain the confidentiality of all information received 
or developed in connection with this Protocol . 
(Printed Name of Investigator)  
(Signature of Investigator)  (Date)  
Incyte Corporation  Page 3 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046 CONFIDENTIAL  TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...1 
INVESTIGATOR'S AGREE MENT  ................................ ................................ ................................ 2 
TABLE OF CONTENTS  ................................ ................................ ................................ ................. 3 
LIST OF ABBR EVIATIONS  ................................ ................................ ................................ ........ 10 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 13 
2. INTRODUCTION  ................................ ................................ ................................ ......19 
2.1. Backgro und ................................ ................................ ................................ ................. 19 
2.2. Product Information and Overview of Itacitinib  ................................ ........................ 20 
2.2.1.  Nonclinical Drug Metabolism and Pharmacokinetics  ................................ ................ 20 
2.2.2.  Clinical Drug Metabolism and Pharmacokinetics  ................................ ...................... 21 
2.2.3.  Itacitinib Clinical Safety Summary  ................................ ................................ ............ 23 
2.3. Study Rationale  ................................ ................................ ................................ ........... 23 
2.3.1.  Scientific Rationale for Study Design  ................................ ................................ ........ 24 
2.3.2.  Justification for Dose, Part 1  ................................ ................................ ...................... 25 
2.3.3.  Preliminary Results from Part 1  ................................ ................................ ................. 25 
2.3.4.  Rationale for Part 2  ................................ ................................ ................................ .....26 
2.4. Benefit/Risk Assessment  ................................ ................................ ............................ 27 
2.5. Preclinical Summary  ................................ ................................ ................................ ...27 
2.5.1. Preclinical Summary Conclusions  ................................ ................................ .............. 30 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 31 
4. STUDY DESIGN  ................................ ................................ ................................ .......32 
4.1. Overall  Design  ................................ ................................ ................................ ............ 32 
4.2. Overall Study Duration  ................................ ................................ ............................... 33 
4.3. Study Termination  ................................ ................................ ................................ ......33 
5. STUDY POPULATION  ................................ ................................ ............................. 34 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 34 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......35 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 36 
5.4. Screen Failures  ................................ ................................ ................................ ............ 37 
5.5. Replacement of Participants  ................................ ................................ ....................... 37 
6. STUDY TREATMENT  ................................ ................................ .............................. 37 
Incyte Corporation  Page 4 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046 CONFIDENTIAL  6.1. Study Treatment Administered  ................................ ................................ ................... 37 
6.1.1.  Study Treatment Preparation, Handling, and Accountability  ................................ .....38 
6.1.2.  Study Treatment Complia nce ................................ ................................ ..................... 38 
6.1.3.  Dose Modifications for Itacitinib  ................................ ................................ ................ 39 
6.1.4.  Criteria for Permanent Discontinuation of Study Treatment  ................................ ......39 
6.2. Immune Effector Cell Therapy  ................................ ................................ ................... 39 
6.3. Measures to Minimize Bias:  Randomization and Blinding  ................................ .......40 
6.4. Concomitant Medications and Procedures  ................................ ................................ .40 
6.4.1.  Permitted Medications and Procedures  ................................ ................................ ......40 
6.4.2.  Restricted Medications and Procedures  ................................ ................................ ......40 
6.4.3.  Prohibited Medications and Procedures  ................................ ................................ .....41 
6.5. Treatment After the End of the Study  ................................ ................................ ......... 41 
7. DISCONTINUATION OF S TUDY TREATMENT AND P ARTICIPANT
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..41 
7.1. Discontinuation of Study Treatment  ................................ ................................ ........... 41 
7.1.1.  Reasons for Discontinuation  ................................ ................................ ....................... 41 
7.1.2.  Discontinuation Procedures  ................................ ................................ ........................ 42 
7.2. Participant Withdrawal From the Study  ................................ ................................ .....42 
7.3. Lost to Follow -Up................................ ................................ ................................ .......42 
7.4. Study Treatment Completion  ................................ ................................ ...................... 43 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 44 
8.1. Administrative and General Procedures  ................................ ................................ .....44 
8.1.1.  Informed Consent Process  ................................ ................................ .......................... 44 
8.1.2.  Screening Procedures  ................................ ................................ ................................ ..45 
8.1.3.  Interactive Response Technology Procedure  ................................ .............................. 45 
8.1.4.  Distribution of Reminder Cards  ................................ ................................ .................. 45 
8.1.5.  Demography and Medical History  ................................ ................................ .............. 45 
8.1.5.1.  Demographics and General Medical History  ................................ ............................. 45 
8.1.5.2.  Disease Characteristics and Treatment History  ................................ .......................... 46 
8.2. Efficacy and Endpoint Assessments  ................................ ................................ ........... 46 
8.2.1.  CRS Status  ................................ ................................ ................................ .................. 46 
8.2.2.  ICANS Status ................................ ................................ ................................ .............. 46 
8.2.3.  Lee's CRS Revised Grading System  ................................ ................................ ........... 48 
Incyte Corporation  Page 5 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  8.3. Safety Assessments  ................................ ................................ ................................ .....49 
8.3.1.  Adverse Events  ................................ ................................ ................................ ........... 49 
8.3.2.  Physical Examinations  ................................ ................................ ................................ 50 
8.3.3.  Vital Signs and Temperature Monitoring  ................................ ................................ ...50 
8.3.4.  Eastern Cooperative Oncology Group Performance Status  ................................ ........ 50 
8.3.5.  Local Laboratory Assessments  ................................ ................................ ................... 51 
8.3.5.1.  Pregnancy Testing  ................................ ................................ ................................ ......52 
8.3.5.2.  Serology  ................................ ................................ ................................ ...................... 53 
8.4. Hematologic Disease Status  ................................ ................................ ....................... 53 
 53 
 54 
8.7. Unscheduled Visits  ................................ ................................ ................................ .....55 
8.8. End of Treatment  ................................ ................................ ................................ ........ 55 
8.9. Follow -Up ................................ ................................ ................................ ................... 55 
8.9.1.  Safety Follow -Up ................................ ................................ ................................ ........ 55 
8.9.2. Hematologic Disease Follow -Up ................................ ................................ ................ 56 
8.9.3.  Electrocardiograms and Echocardiograms  ................................ ................................ .56 
8.9.4.  Survival Follow -Up ................................ ................................ ................................ ....56 
8.10. End of Study  ................................ ................................ ................................ ............... 56 
9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDU RES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  ...................... 57 
9.1. Definition of Adverse Event  ................................ ................................ ....................... 57 
9.2. Definition of Serious Adverse Event  ................................ ................................ .......... 58 
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse Events  ......... 59 
9.4. Reporting of Serious Adverse Events  ................................ ................................ ......... 61 
9.5. Adverse Events of Special Interest  ................................ ................................ ............. 62 
9.6. Emergency Unblinding of Treatment Assignment  ................................ ..................... 62 
9.7. Pregnancy  ................................ ................................ ................................ ................... 63 
9.8. Warnings and Precautions  ................................ ................................ .......................... 63 
9.9. Product Complaints  ................................ ................................ ................................ ....63 
9.10.  Treatment of Overdose  ................................ ................................ ............................... 64 
10. STATISTICS  ................................ ................................ ................................ .............. 65 
10.1.  Sample Size Determination  ................................ ................................ ........................ 65 

Incyte Corporation  Page 6 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  10.2.  Populations for Analysis  ................................ ................................ ............................. 66 
10.3.  Level of Significance  ................................ ................................ ................................ ..67 
10.4.  Statistical Analyses  ................................ ................................ ................................ .....67 
10.4.1.  Primary Analysis  ................................ ................................ ................................ ........ 67 
10.4.1.1.  CRS Rate by Day 14  ................................ ................................ ................................ ...67 
10.4.1.2.  Cytokine Release Syndrome Rate by Day 14 â€“ Part 2  ................................ ............... 67 
10.4.2.  Secondary Analysis  ................................ ................................ ................................ ....67 
10.4.2.1.  Part 2 Analysis  ................................ ................................ ................................ ............ 67 
10.4.2.2.  ICANS Incidence  ................................ ................................ ................................ ........ 68 
10.4.2.3.  Onset and Duration of ICANS  ................................ ................................ .................... 68 
10.4.2.4.  Onset and Duration of CRS  ................................ ................................ ........................ 68 
10.4.2.5.  Occurrence of CRS Within 48 Hours  ................................ ................................ ......... 68 
10.4.2.6.  CRS Rate Within 28 Days  ................................ ................................ .......................... 68 
10.4.2.7.  Hospitalization on Study  ................................ ................................ ............................. 68 
10.4.3.  Safety Analyses  ................................ ................................ ................................ .......... 69 
10.4.3.1.  Adverse Events  ................................ ................................ ................................ ........... 69 
10.4.3.2.  Clinical Laboratory Tests  ................................ ................................ ........................... 69 
10.4.3.3.  Vital Signs  ................................ ................................ ................................ .................. 69 
10.4.3.4.  Dose Intensity  ................................ ................................ ................................ ............. 70 
 70 
 70 
 70 
 70 
10.5.  Interim Analysis  ................................ ................................ ................................ .......... 70 
11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..72 
11.1.  Investigator Responsibilities  ................................ ................................ ....................... 72 
11.2.  Data Management  ................................ ................................ ................................ .......73 
11.3.  Data Quality Assurance  ................................ ................................ .............................. 75 
11.4.  Data Privacy and Confidentiality of Study Records  ................................ ................... 75 
11.5.  Financial Disclosure  ................................ ................................ ................................ ...76 
11.6.  Publication Policy  ................................ ................................ ................................ .......76 
11.7.  Study and Site Closure ................................ ................................ ................................ 77 

Incyte Corporation  Page 7 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  12. REFERENCES  ................................ ................................ ................................ ........... 78 
APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S ................................ ................................ ............... 80 
APPENDIX  B. CYTOCHROME P450 AND P-GLYCOPROTEIN INHIB ITORS 
AND CYTOCHROME P450 INDUCERS  ................................ ................................ 81 
APPENDIX  C. INSTRUCTION TO PARTI CIPANTS FOR HANDLING  STUDY 
TREATMENT  ................................ ................................ ................................ ............ 82 
APPENDIX  D. MANAGEMENT OF POTENT IAL HY'S LAW CASES  ................................ 83 
APPENDIX  E. RESPONSE CRITERIA FO R LYMPHOMA â€“ THE LUG ANO 
CLASSIFICATION  ................................ ................................ ................................ ....87 
APPENDIX  F. RESPONSE CRITERIA FO R ACUTE LYMPHOBLASTIC 
LEUKEMIA  ................................ ................................ ................................ ............... 89 
APPENDIX  G. PROTOCOL AMENDMENT S UMMARY OF CHANGES  ........................... 91 
 
Incyte Corporation  Page 8 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  LIST OF TABLES  
Table  1: Primary and Major Secondary Objectives and Endpoints  ................................ .......... 13 
Table  2: Key Study Design Elements  ................................ ................................ ....................... 14 
Table  3: Schedule of Activities  ................................ ................................ ................................ .16 
Table  4: Summary of Itacitinib Steady -State (Day 7) Pharmacokinetic Parameters by 
Actual Dose Regimen  ................................ ................................ ................................ .22 
Table  5: Summary of Itacitinib Steady -State (Day 7) Pharmacokinetic Parameters by 
Actual Dose Regimens and Concomitant CYP3A4 Inhibitors  ................................ ...23 
Table  6: Enzyme Inhibitory Activity of Itacitinib Against Different Members of the 
Human JAK Family  ................................ ................................ ................................ ....28 
Table  7: Objectives and Endpoints  ................................ ................................ ........................... 31 
Table  8: Exclusionary Laboratory Values  ................................ ................................ ................ 36 
Table  9: Study Treatment Information  ................................ ................................ ..................... 37 
Table  10: ASBMT CRS Consensus Grading  ................................ ................................ .............. 46 
Table  11: Encephalopathy Assessment Tool for Grading of Immune Effector Cell â€“
Associated Neurotoxicity Syndrome  ................................ ................................ .......... 47 
Table  12: ASBMT Immune Effector Cell â€“Associated Neurotoxicity Syndrome 
Consensus Grading  ................................ ................................ ................................ .....48 
Table  13: Lee CRS Revised Grading System  ................................ ................................ ............. 49 
Table  14: Eastern Cooperative Oncology Group Performance Status Scoring  .......................... 51 
Table  15: Required Laboratory Analytes  ................................ ................................ .................... 52 
 54 
 55 
Table  18: CRS Rates and 95% Confidence Intervals  ................................ ................................ .65 
Table  19: Bayesian Posterior Probability of Demonstrating a Treatment Difference  ................ 66 
Table  20: Populations for Analysis  ................................ ................................ ............................. 66 
 

Incyte Corporation  Page 9 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  LIST OF FIGURES  
Figure  1: Study Design Schema Part 1  ................................ ................................ ....................... 15 
Figure  2: Study Design Schema Part  2 ................................ ................................ ....................... 15 
Figure 3:  Simulated Free Itacitinib Concentration -Time Profiles  ................................ .............. 26 
Figure  4: Effect of Increasing Itacitinib Concentrations on CAR -T Cell Proliferation 
and Effector Function  ................................ ................................ ................................ .28 
Figure  5: Itacitinib Effect on CD19 -CAR -T Cells In Vivo Antitumor Activity  ........................ 29 
Figure  6: Itacitinib Effect on CAR -T Cells Production of Inflammatory Cytokines  ................. 30 
Incyte Corporation  Page 10 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  LIST OF ABBREVIATION S 
Abbreviation s and 
Special Terms  Definition  
AAGP  Î±-1-acid glycoprotein  
AE adverse event  
ALL  acute lymphoblastic leukemia  
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
ASBMT  American Society for Blood and Marrow Transplantation  
AST  aspartate aminot ransfer ase 
ASTCT  American Society for Transplant and Cellular Therapy  
BCRP  breast cancer resistance protein  
BID twice daily  
CAR  chimeric antigen receptor  
CAR -T chimeric antigen receptor therapy  
CFR  Code of Federal Regulations  
Cmax maximum serum concentration of drug after administration  
CNS  central nervous system  
CR complete response  
CRES  chimeric antigen receptor T -cellâ€“related encephalopathy syndrome  
CRi complete response with incomplete blood count recovery  
CRP  C-reactive protein  
CRS  cytokine release syndrome  
CSF cerebral spinal fluid  
CSR  Clinical Study Report  
CTCAE  v5.0 Common Terminology Criteria for Adverse Events  version 5.0  
DDI drug-drug interaction  
DNA  deoxyribonucleic acid  
DSMB  Data Safety Monitoring Board   
EAS  evaluable analysis set  
ECG  electrocardiogram  
ECHO  echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture  
EOS  end of study  
EOT  end of treatment   
Incyte Corporation  Page 11 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Abbreviation s and 
Special Terms  Definition  
FDA  Food and Drug Administration  
FDG -PET fluorodeoxyglucose positron  emission tomography  
GCP  Good Clinical Practice  
GFR  glomerular filtration rate  
GVHD  graft -versus -host disease  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HSA  human serum albumin  
IB Investigator 's Brochure  
ICANS  immune effector cell â€“associated neurotoxicity syndrome  
ICE immune effector cell â€“associated encephalopathy  
ICF informed consent form  
ICH International Council on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
IEC immune effector cell  
IFN-Î³ interferon -gamma  
IL-1 interleukin -1 
IL-6 interleukin -6 
IL-6R interleukin -6 receptor  
IRB institutional review board ( or ethics committee)  
IRT interactive response technology  
JAK Janus kinase  
LVEF  left ventricular ejection f raction  
  
   
OVA  ovalbumin  
  
PD progressive disease  
PK pharmacokinetic  
PR partial response  
QD once daily  
RBC  red blood cell  
RNA  ribonucleic acid  
SAE  serious adverse event  
SoA schedule of activities  

Incyte Corporation  Page 12 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Abbreviation s and 
Special Terms  Definition  
SOP standard operating procedure  
STAT  signal transducer and activator of transcription pathway  
TEAE  treatment -emergent adverse event  
TYK  tyrosine kinase  
ULN  upper limit of normal  
WBC  white blood cell  
Incyte Corporation  Page 13 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  1. PROTOCOL  SUMMARY  
Protocol  Title:   A Phase 2  Study of Itacitinib  for the Preventi on of Cytokine Release Syndrome 
Induced by Immune Effector Cell Therapy  
Protocol Number:   INCB 39110 -211 
Objectives and Endpoints : 
Table  1 presents the primary and major secondary objectives and endpoints.  
Table  1: Primary and Major Secondary Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the efficacy of itacitinib  as a 
preventative treatment for CRS associated with 
IEC therapy . Efficacy , as determined by the proportion of 
participants who develop â‰¥ Grade 2 CRS by Day 1 4 
using  ASBMT CRS Consensus Grading . 
Secondary  
To evaluate the proportion of participants with  
ICANS regardless of CRS, after IEC therapy.  Incidence  and severity of ICANS , as determined by 
the proportion of participants  with ICANS by 
Day 28, after IEC therapy using  the ICANS 
Consensus Grading.  
To evaluate the onset and episode of ICANS 
using  the ICANS Consensus Grading, regardless 
of CRS, by Day 28.  Time to onset and d uration of ICANS using  the 
ICANS Consensus Grading, regardless of CRS, by 
Day 28.  
To evaluate the duration of all grade s of CRS,  
by Day 28.  Time to onset and d uration of all grade s of CRS by 
Day 28 using  ASBMT CRS Consensus Grading.  
To evaluate the proportion of participants who 
develop any grade of CRS within 48 hours after 
IEC therapy.  Proportion of participants  with any grade C RS at 
48 hours, after IEC therapy using  ASBMT CRS 
Consensus Grading.  
To evaluate the proportion of participants  who 
develop â‰¥  Grade 2 CRS by Day 28 of 
administration after first IEC therapy.  Proportion of participants  with â‰¥ Grade 2 CRS by 
Day 28, after first IEC therapy.  
To characterize the safety of itacitinib, before 
and after IEC th erapy, excluding CRS and 
ICANS.  Safety of itacitinib assessed by the incidence of all 
AEs except CRS and ICANS, by collecting 
laboratory data, performing physical examinat ions, 
and collecting vital signs beginning at Day â€“3 and 
through the duration of safety follow -up. 
â‰¥ Grade 3 Cytopenias  ongoing by Day 30.  
To assess intervention for CRS and ICANS . Proportion of participants who were treated with 
tocilizumab for CRS.  
Proportion of participants requiring more than 
1 dose of dexamethasone (or equivalent) for 
ICANS.  
Incyte Corporation  Page 14 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Overall Design:  
Table  2 presents the key study design elements.  Further study details are presented after the 
table.  
Table  2: Key Study Design Elements  
Study  Phase  Phase 2  
Clinical Indication  Prevention of CRS  after IEC therapy  
Population  Male or female participants aged 12 years or older eligible to receive an 
approved immune effector cell (IEC) therapy for hematologic 
malignancies.   
Number of Participants  Part 1:  Approximately 62 participants  
Part 2:  Approximately 46 evaluable participants  (23 participants  per 
arm)  
Study Design  This is a 2 -part study designed to assess the safety and efficacy of oral 
administration of itacitinib to participants planning to recei ve IEC 
therapy.  In Part 1, participants will be administered open label itacitinib 
200 mg QD.  In Part 2, participants will be randomized to receive either 
itacitinib 200  mg BID or placebo.  
Study treatment will begin on Day â€“3 (pre -IEC) and continue throu gh 
Day 26 (study treatment period).  IEC therapy will be administered on 
Day 0 (IEC  infusion day).  Protocol -defined a ssessments will be 
conducted on Days  â€“3, â€“1, 0, 1, 3, 5, 7, 14, 21, and 28 (see  Table  3).  
Restaging of disease will be conducted as applicable per institutional 
guidelines.  A completer is defined as a participant who completes 30 
days (Day  â€“3 to Day 26) of study treatment admi nistration.  Safety will 
be monitored beginning at screening and continue until 30 days after the 
last dose of study treatment.  
Additional post -therapy follow -up visits will be conducted at Day 90 
and Day  180 (90 and 180 days after IEC).  End of study is m et at Day 
180 (6  months after IEC).  All participants should complete a Day 28 
assessment, unless the participant withdraws consent, even if treatment 
ends early.  
Estimated Duration of 
Study Participation  This study includes a 14 -day screening period.  Enrollment and study 
treatment administration begin on Day â€“3 (Day 0 = IEC infusion day).  
Study treatment continues through Day 26.  The participant will 
continue to be assessed for survival follow -up for 6 months, with a final 
EOS assessment at Day 180.  Hematologic disease assessments that are 
conducted during this time should be captured in the eCRF.  
DSMB  Internal  
Coordinating Principal 
Investigator   MD 
 
 
Treatment Groups and Duration:  
This Protocol includes a 14-day screening period after apheresis.  

Incyte Corporation  Page 15 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  This Protocol includes  treatment with  IEC therapy  administered p er the prescribing label on 
Day 0. 
In Part 1,  study treatment is defined as  itacitinib beginning at Day â€“3 (pre-IEC)  using  itacitinib  
200 mg QD through Day 2 6 (30 days of treatment).  
In Part 2,  study treatment is defined as itacitinib 200 mg BID or placebo beginning at Day â€“3 
(pre-IEC) through Day 26 (post -IEC), counting for a  total of 30 days of treatment.  
See Figure  1 for the study design and Table  3 for the SoA.  Adherence  to the study design 
requirements, including those specified in the SoA, is essential and required for study conduct.  
Figure  1: Study Design Schema  Part 1  
 
Figure  2: Study Design Schema Part 2  
 
 

Incyte Corporation  Page 16 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  3: Schedule of Activities  
 Screeninga Study Treatment  Post-Treatment Follow -Upa 
Protocol 
Section  D â€“17 to D  â€“4 D â€“3 D â€“1 IEC 
D0 D1 D3 D5 D7 D14 
(Â± 2 d) D21 
(Â± 2 d) EOTb 
D28 
(Â± 2 d) D56 
30 d After 
Last Dose 
(Â± 3 d) D90 
(Â± 1 wk) EOS  
D180 
(Â± 2 wk) 
Administrative procedures  
Informed consent  X              8.1.1  
Contact IRT  X X         X    8.1.3  
Inclusion/exclusion criteria  X X X            5.1, 5.2 
Demography/medical history  X              8.1.5  
Prior/concomitant medications  X X X X X X X X X X X X   6.3 
Administer study treatment   X X X X X X X X X     6.1 
Administer IEC therapy     X           6.2 
Document compliance   X X X X X X X X X X    6.1.2  
Dispense reminder cards  X X X X X X X X X X X X X  8.1.4  
Drug accountability   X X X X X X X X X X    6.1.1  
Survival follow -up             X X 8.9.4  
Safety assessments  
Adverse events  X X X X X X X X X X X X   8.3.1  
ECOG  X  X      X  X    8.3.4  
Physical examination  X  X        X    8.3.2  
Vital signs  X X X X X X X X X X X X   8.3.3  
ECHO  X Only if clinically relevant    8.9.3  
12-lead ECG  X Only if clinically relevant    8.9.3  
Disease assessments  
FDG -PET CT/MRIc X          X  X X 8.4 
Bone marrow evaluation  X          Only if clinically relevant  8.4 
Endpoint assessments  
Temperature monitoring   X X X X X X X X X X    8.3.3  
CRS assessment (ASBMT CRS 
consensus grading)d   Continuous monitoring based on fever  X   8.2.1  
ICANS assessment (ASBMT ICE 
consensus grading)e   Continuous monitoring based on signs and symptoms  X   8.2.2  
Lee's CRS revised grading system    X X X X X X X X X X   8.2.3  
Incyte Corporation  Page 17 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  3: Schedule of Activities (Continued)  
 Screeninga Study Treatment  Post-Treatment Follow -Upa 
Protocol 
Section  D â€“17 to D  â€“4 D â€“3 D â€“1 IEC 
D0 D1 D3 D5 D7 D14 
(Â± 2 d) D21 
(Â± 2 d) EOTb 
D28 
(Â± 2 d) D56 
30 d After 
Last Dose 
(Â± 3 d) D90 
(Â± 1 wk) EOS  
D180 
(Â± 2 wk) 
Local laboratory assessmentsf 
Hematology  X X  X X X X X X X X X X  8.3.5  
Serum chemistries (including LDH)  X X  X X X X X X X X    8.3.5  
Coagulation panel  X X     X    X    8.3.5  
Lipid panel  X          X    8.3.5  
Hepatitis screening  X              8.3.5.2  
Pregnancy testing  X X         X X   8.3.5.1  
Lumbar puncture with paired blood 
samplesg Only if performed based on SOC     â€” 
Urinalysis  X          X    8.3.5  
CRP  X X  X X X X X X X X    8.3.5  
Ferritin levels  X X  X X X X X X X X    8.3.5  
ASBMT = Association for Blood and Bone Marrow Transplantation; CRP = C -reactive protein; CRS = cytokine release syndrome; CT = computed tomography; 
ECG  = electrocardiogram; ECHO = echocardiogram; ECOG = Eastern Cooperative Oncology Group; EOS = end of study; EOT = end of treatment; 
FDG -PET = fluorodeoxyglucose positron emission tomography; ICANS = immune effector cell â€“associated neurotoxicity syndrome; ICE  = immune effector cell â€“associated 
encephalopathy; IEC = immune effector cell; LDH  = lactase dehydrogenase; MRI = magnetic resonance imaging; PBMC = peripheral blood mononuclear cell; 
PK = pharmacokinetics; SOC = standard of care.  
a Decentralized assessments are acceptable during screening and post -treatment (see Section  11.1). 
b EOT:  Treatment will end on Day 26; however, the participant will be assessed at Day 28 Â± 2 days.  If a participant ends trea tment early, an EOT visit should be conducted at the 
time that the participant discontinues treatment.  
c If hematologic disease assessments are performed at different timepoints, based on institutional guidelines, then this is acc eptable.  All disease assessments should be captured in 
the eCRF.  
d CRS will be evaluated at each visit during the study. In addition, participants should monitored be during the study and eval uated for CRS if fever is present.  
e ICANS will be evaluated at each visit during the study. In addition, participants should be monitored during the study and ev aluated for ICANS if there are signs and symptoms 
relating to neurot oxicity.  

Incyte Corporation  Page 18 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  f Screening for central laboratory assessments must be performed within 7 days of Day â€“3.  If screening laboratory assessments are performed within 3 days before Day â€“3, then 
the tests d o not need to be repeated on Day âˆ’3.  Any laboratory samples collected on Day â€“3 must be collected before study treatment administration.  
g Lumbar puncture is not required; however, if one is per formed per SOC, then it should be captured in the eCRF.  
 
Incyte Corporation  Page 19 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  2. INTRODUCTION  
2.1. Background  
Cytokine -related diseases or disorders are characterized by excessive immune activation and 
include CRS, hemophagocytic lymphohistiocytosis , macrophag e activati on syndrome , and 
ICANS.  
Cytokine release syndrome is a result of overproduction of inflammatory cytokines caused by 
robust and rapid immune activation and is manifested as a clinical constellation of symptoms 
including fever, nausea, fatigue, myalgia, mala ise, hypotension, hypoxia, and capillary lea k, 
resulting in potential multi organ toxicity.  
CRS has been observed as a consequence of various  immune -based therapies such as 
monoclonal antibodies  and, more recently, adoptive T -cell therapies for cancer  (Lee et al 2014 ).  
Examples of FDA -approved CAR T-cell therap ies include axicabtagene ciloleucel  and 
tisagenlecleucel, both being engineered T-cell produc ts used in refractory CD19+ B -cell 
malignancies such as non-Hodgkin 's lymphoma  and pediatric relapsed /refractory  ALL.   
Brexucabtagene autoleucel  was recently FDA approved  as well .  This product is a CD19 -directed 
genetically modified autologous T cell immunotherapy indicated for the treatment of adult 
patients with relapsed o r refractory mantle cell lymphoma ( Tecartus  2020 ). 
The cytokine profiles involved in CRS encompass 2 main cellular sources:   
T lymphocyte â€“derived cytokines including  IFN-Î³, IL -2, IL -6, and granulocyte  macrophage  
colony -stimulating factor,  and cytokines mainly secreted by monocytes and/or macrophages such 
as IL -1Î², IL -6, IL -12, IL -18, an d TNF -Î± (Brentjens et  al 2010 , Xu and Tang  2014 , Zhang 
et al 2016 ). 
Modulation of the exaggerated cytokine response resulting in CRS has the potential to provide 
significant clinical benefit.  For example, tocilizumab, a  humanized monoclonal  antibody against 
the IL -6R, decreases the  rates of severe CRS and is FDA -approved for use in CRS  (Le et al 2018 ).  
However, tocilizumab 's mechanism of ac tion is restricted to anti â€“IL-6 only.  
The CRES i s the second most common AE, after CRS, associated with CAR -T-cell 
therapy.   CRES (or ICANS) is characterized by a toxic encephalopathy state with symptoms of 
confusion , delirium , occasiona l seizures and cerebral edema.  The manifestation of CRES can be 
biphasic with symptoms occurring within the first 5 days and/or 3  to 4 weeks after cellular 
immunotherapy.   The pathophysiological mechanism is believed to involve passive diffusion of 
cytokines into the CNS  of patients treated with CAR -T-cell therapy.   The reduction or 
elimination of this mechanism can be beneficial to such p atients  (Neelapu et al 2018 ).  While 
targeting IL -6 with tocilizumab has been effective in the management of CRS, it does not 
attenuate symptoms o f neurotoxicity and is currently not FDA appr oved for the treatment of 
CRES  (Kotch et al 2019 , Teachey et a l 2016 ). 
Incyte Corporation  Page 20 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  2.2. Product Information and Overview of Itacitinib  
Itacitinib represents a novel, potent, and selective inhibitor of the JAKs with selectivity for 
JAK1.  There are 4 known JAK family membe rs, JAK1, JAK2, JAK3, and TYK2.  
The pharmacology and additional details on toxicology of itacitinib are described in the  itacitini b 
IB.  In brief, itacitinib potently inhibits JAK1 (IC 50 = 3.6  nM) with 22 - to > 500 -fold selectivity 
compared with JAK2, JAK3, and TYK2, and it does not significantly inhibit a broad panel of 
approximately  60 other kinases.  Itacitinib is potent (IC 50 values 10 -100 nM) in cytokine -driven 
cell-based assays, such as IL -2â€“stimulated phosphorylation of JAKs and STATs and IL -2induced 
proliferation of primary human T cells.  Itacitinib inhibits the growth of the cytokine -dependent 
cell line INA -6, this effect is not due to general cytotoxicity.  Itacitinib potently inhibits the 
phosphorylation of STAT proteins and the production of proinflammatory factors (eg, IL -17, 
MCP -1) induced by cytokines such as IL -23 and IL -6 (IC 50 ~30-100 n M).  In contrast, itacitinib 
shows less inhibition in cell -based assays dependent on JAK2 (eg, thrombopoietin  or prolactin -
stimulated STAT phosphorylation) with IC 50 approximately  1 Î¼M or greater, suggesting that 
itacitinib is JAK2 -sparing in cells.  In in  vivo models of JAK -dependent malignancy, itacitinib 
impedes subcutaneous tumor growth of INA -6 cells expressing wild -type JAKs plasma 
concentrations well below those necessary to inhibit JAK2.  Moreover, oral itacitinib improved 
splenomegaly in a JAK2 V61 7Fâ€“driven neoplasia model of MF.  
Administration of itacitinib did not result in QT prolongation or cardiovascular effects.  Adverse 
findings were noted only at high dose (1000 mg/kg) suggesting the primary toxicities are 
expected to be on -target , and these  observations are considered to be well beyond the needed 
safety margin compared to the therapeutic dose.  
In summary, pharmacological data obtained in both in vitro and in vivo model systems support 
the potential utility of orally administered itacitinib i n the treatment of MF.  
2.2.1.  Nonclinical Drug Metabolism and Pharmacokinetics  
In single -dose PK studies in rats, dogs, and monkeys, orally administered itacitinib was rapidly 
absorbed (t max â‰¤ 2.0 hours).  The protein binding of itacitinib in plasma and serum from rats, 
dogs, and humans was moderate (unbound fraction of 29% -43%) and not depende nt on itacitinib 
concentration.  
In a separate in vitro experiment.  The protein binding of itacitin ib was determined using HSA 
and AAGP at concentrations ranging from 0.3  to 1.0 Î¼M.  The unbound fractions of itacitinib 
0.3 and 1.0 Î¼M in 40 mg/mL HSA were 31.2% and 32.7% , respectively (aligned with previous 
results); in 25 mg/mL HSA were 41.5% and 42.6%, respectively; and in 10 mg/mL HSA were 
60.9% and 61.7%, respectively.  The unbound fractions in AAGP were 85.5% and 89.5% at 
0.3 Î¼M and 1.0 Î¼M, respectively.  The free fraction in HSA was independent of compound 
concentration.  The free fraction in HSA decreased with increasing protein concentration.   The 
free fraction in AA GP was independent of compound concentration.   In male rats administered a 
4-hour IV infusion of itacitinib, the average brain homogenate concentration of itacitinib at 
4 hours was 6.18% of the corresponding total plasma concentration, while the average CSF 
concentration was 2.93% of the corresponding free plasma concentration, suggesting minimal 
penetration across th e blood -brain barrier in rats.  
Incyte Corporation  Page 21 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Transport studies using Caco -2 monolayers show that itacitinib is likely a substrate for P -gp, and 
the efflux t ransport is likely saturated when the itacitinib concentration is greater than 300  Î¼M.  
In addition, the bidirectional transport ratio of digoxin (a P -gp substrate) decreased in the 
presence of itacitinib in a concentration -dependent manner, with an IC 50 of 41.4  Î¼M, indicating 
that itacitinib is a weak P -gp inhibitor.  The interaction of itacitinib with human BCRP was also 
determined in MDCKII -BCRP cells.  The net efflux ratio of itacitinib was 3.3 at 10 ÂµM, 
suggesting that itacitinib is a substrate of BCRP .  Itacitinib is not an inhibitor of BCRP.   Given 
the moderate solubility and permeability of itacitinib, and marginal efflux in the gut at the 
proposed clinical doses, a DDI study with a P -gp/BCRP inhibitor may not be clinically relevant.  
In addition, ba sed on physiologically based pharmacokinetic modeling, a clinical DDI study with a 
P-gp substrate such as digoxin may not need to be considered ( EMA 2012 , FDA 2017 ). 
CYP3A4 is the major isozyme responsible for the metabolism of itacitinib.  Itacitinib did not 
inhibit or induce CYP activity, suggesting a low potential for DDIs. 
In vitro studies also demonstrated that itacitinib is not a substrate of hepatic transporters 
OATP1B1/1B3 or renal transp orter OCT2.  Although itacitinib inhibited the hepatic transporters 
OATP1B1/1B3 and renal transporters OAT1/3, OCT2, and MATE1/2K, the potential to cause a 
clinical DDI is low.  Overall, DDI mediated by the major drug transporters for itacitinib is 
unlikel y at the proposed clinical doses.  
2.2.2.  Clinical Drug Metabolism and Pharmacokinetics  
Coadministration with a high -fat meal increased Cmax by 22% and AUC 0-âˆž by 30% following a 
single dose of itacitinib 200 mg compared with administration in the fasted state.  Th is increase 
is not clinically significant , and itacitinib may be administered without regard to food.   Itacitinib 
displays suprap roportional PK, that is,  exposure increases greater than proportionally with 
increasing dose.  
A single dose of three 100 mg SR3  tablets of itacitinib followed by an oral solution of 
[14C]itacitinib adipate approximately 500 Î¼Ci free base equivalent was administered to 7 healthy 
participants in Study INCB 39110 -109.  A mean of 71.7% of the dose was recovered in feces, 
and 24.5% was  recovered in urine through the last collection interval.  The overall mean 
recovery of radioactivity in urine and fec al samples was 96.2% by the end of the 240 -hour study 
period.  No major metabolites (â‰¥ 10% of total drug -related material) were detected i n plasma , 
and itacitinib was the major circulating species in plasma.  Itacitinib was the major species in 
urine and feces.  All metabolites identified in urine and feces accounted for < 10% of the 
excreted dose each.  
Based on data from the renal impairment Study INCB  39110 -122, total (AUC 0-âˆž) and maximal 
exposure (C max) increased by 2.23 -fold (90% CI:  1.56, 3.18) and 1.65 -fold (90% CI:  1.13, 
2.39), respectively, in participants with severe renal impairment compared w ith participants with 
normal renal function.  However, there was no notable change in total or maximal exposure in 
participants with end -stage renal disease receiving dialysis predose or 4 hours postdose.  
In participants with moderate hepatic impairment, t otal (AUC 0-âˆž) and maximal exposure (C max) 
increased by 2.51 -fold (90% CI:  1.54, 4.08) and 1.95 -fold (90% CI:  1.14, 3.35), respectively, 
compared with normal participants ( Study INCB 39110 -113).  In participants with severe hepatic 
Incyte Corporation  Page 22 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  impairment, total (AUC 0-âˆž) and maximal exposure (C max) increased by 4.08 -fold (90% CI:  2.41, 
6.89) and 3.48 -fold (90% CI:  1.94, 6.23), respectively, compared with normal participants.  
Study INCB  39110 -115 demonstrated that, while itacitinib may increase serum creatinine in 
some participants, there was no effect on GFR as measured by iohexol clearance.  
A post -hoc ECG exposure -response analysis was conducted to assess the cardiac safety of 
itacitinib using data from the first -in-human study , INCB 39110 -101.  Itacitinib at the stu died 
doses did not have a relevant effect on cardiac conduction.  A QTc effect exceeding the threshold 
of concern (10 ms) can be excluded within the observed range of itacitinib plasma concentrations 
(ie, up to ~13,000 nM, which is expected to be well-abov e the maximum concentration expected 
in various subpopulations [eg, renal impairment] receiving therapeutic itacitinib).  
In a pilot study in a cute GVHD participants  (Study INCB 39110 -108), characterization of the PK 
of itacitinib after single and multiple doses of itacitinib was performed.  In this study, doses of 
200 mg or 300  mg QD were administered and appear to display similar PK in this participant 
population, noting the small sample size ( see Table  4).  Additionally, participants who were 
concomitantly on a strong CYP3A4 inhibitor, mainly posaconazole, appeared to have exposures 
(AUC 0-Ï„) approximately 2  Ã— higher than those who were not concomitantly o n a strong CYP3A 
inhibitor ( see Table  5).  Based on preliminary data, exposures following 200  mg QD were 
similar in a Phase 3 study in a cute GVHD particip ants as compared to the pilot study.  
Additionally, based on preliminary data from this Phase 3 study, exposures in participant s 
concomitantly receiving posaconazole were similar to those concomitantly receiving 
voriconazole , supporting similar dosing reco mmendations for itacitinib when coadministered 
with any strong CYP3A inhibitor regardless of the specific inhibitor.  
Table  4: Summary of Itacitinib Steady -State (Day 7) Pharmacokinetic Parameters by 
Actual Dose Regimen  
Actual 
Regimen  No. of Participants  Cmax (nM)  tmax(h) Ctau (nM)  AUC tau (nMâ€¢h)a 
200 mg QD  11 624 Â± 340  
(534)  4.0 
(1.3, 7.0)  64.0 Â± 79.3  
(NC)  5560 Â± 3430  
(4700)  
300 mg QD  13 781 Â± 668  
(484)  2.0 
(0.0, 5.6)  53.1 Â± 64.0  
(NC)  5880 Â± 5170  
(4110)  
NC = not calculable.  
Note:  Values are mean Â± SD (geometric mean) , except t max, which is median (min, max).  
a AUC tau is calculated from time 0 -24 hours postdose, where the 24 -hour concentration is imputed from predose trough.  
Incyte Corporation  Page 23 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  5: Summary of Itacitinib Steady -State (Day 7) Pharmacokinetic Parameters by 
Actual Dose Regimens and Concomitant CYP3A4 Inhibitors  
Actual 
Regimen  CYP3A4 
Inhibitora No. of 
Participants  Cmax (nM)  Tmax (h) Ctau (nM)  AUC tau (nMâ€¢h) 
200 mg 
QD 1 6 580 Â± 341  
(492)  4.2 
(2.1, 7.0)  27.0 Â± 33.2  
(NC)  4240 Â± 2630  
(3720)  
3 5 678 Â± 371  
(589)  2.1 
(1.3, 4.2)  108 Â± 99.2  
(NC)  7140 Â± 3870  
(6250)  
300 mg 
QD 1 6 307 Â± 282  
(204)  1.5 
(0.0, 5.6)  66.5 Â± 85.7  
(36.6)  2920 Â± 1800  
(2320)  
3 7 1190 Â± 639  
(1010)  2.1 
(1.0, 4.8)  41.6 Â± 41.5  
(NC)  8410 Â± 5880  
(6720)  
NC = not calculable.  
Note:  Values are mean Â± SD (geometric mean) , except t max, which is median (min, max).  
a 1 indicates no concomitant CYP inhibitor or mild CYP inhibitor; 3 indicates potent CYP inhibitor.  
2.2.3.  Itacitinib Clin ical Safety Summary  
As of t he data cutoff date ( 30 APR 2021 ), 1699  unique participants have been exposed to 
itacitinib; which includes  543 healthy adult participants.  Thirty four clinical studies with 
itacitinib have been completed or are ongoing.  The studies include those with itacitinib  as 
monotherapy and/or in on e of the following combinations : 
â€¢ Itacitinib in combination with chemotherapeutic agents for the treatment of solid 
tumors.  
â€¢ Itacitinib in combination with a novel PI3KÎ´ inhibitor for the t reatment of lymphoid 
malignancies (INCB040093 or INCB050465).  
â€¢ Itacitinib in combination with INCB050465 for the treatment of solid tumors.  
â€¢ Itacitinib in combination with pembrolizumab for the treatment of solid tumors.  
â€¢ Itacitinib in combination with epacadostat for the treatment of solid tumors.  
â€¢ Itacitinib in combination with corticosteroids for the treatment of acute GVHD.  
â€¢ Itacitinib in combination with osimertinib . 
â€¢ Itacitinib in combination with ibrutinib . 
â€¢ Itacitinib with low -dose ruxolitinib . 
Addit ional details regarding the study designs and primary  endpoints of these studies are 
summarized in the itacitinib IB. 
2.3. Study Rationale  
In AUG 2017, tocilizumab was approved by the FDA for the treatment of severe or 
life-threate ning CAR T  cell-induced CRS.  The approval was based on a retrospective analysis of 
data from patients who developed CRS after treatment with CTL019 tisagenlecleucel 
(KymriahÂ® 2018 ) and axicabtagene ciloleucel KTE -C19 ( YescartaÂ® 2021 ).  The efficacy 
population for the CTL019 cohort included 24 male  and 21 female patients.  The median time 
Incyte Corporation  Page 24 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  from the start of CRS to the first dose of tocilizumab was 4 days (range, 0 -18 days).  Pati ents 
were considered responders if CRS resolved within 14 days of the first dose of tocilizumab, if 
not more than 2  doses of tocilizumab were needed, and if no drugs other than tocilizumab and 
corticoste roids were used for treatment.  Thirty -one patients ( 69%; 95% CI : 53%, 28%) achieved 
a response as described , while an additional  cohort of 15 patients  treated  with KTE -C19â€“induced 
CRS  demonstrated a  53% response rate .  The activity of tocilizumab was supported by a 
literature review.  The available data is wholly insufficient to extend the indication to CRS 
induce d by other immunotherapeutics  (Lee et al 2018 ). 
Neurologic symptoms may result from CRS.  Lee et al  (2014 ) hypothesizes these neurotoxicit ies 
may be related to IL -6 and has been implicated in other neurological diseases such as 
Alzheimer 's, Parkinson 's, multiple sclerosis, sc hizophrenia, and depression .  Elevated levels of 
IL-6 within the CNS  are likely due to  diffusion of peripheral IL -6 into the CNS  or direct 
production within the CNS by CNS residing CAR T cells .  IL-6 levels have been found in the 
cerebrospinal fluid associated with ICANS .  IL-6 levels rise transiently following administration 
of tocilizumab  due to the blockage of the receptor which inhibits receptor -mediated clearance .  
As tocilizumab is not expected to cross the blood brain barrier,  elevated  levels within the CNS 
are not likely to be ameliorated and may even  be transiently aggravated by toc ilizumab therapy  
(Brudno and Kochenderfer 2016 , Lee et al  2014 ).  The seriousness of CRS followed by ICANS  
in the setting of a potentially curative therapy for cancer warrant s as aggressive supportive care 
as possible.  Accordingly, there is a need to develop a new therapy  for the treatment of CRS  
(Hay et al 2019 , Neelapu 2019 , Park et al 2018 ). 
2.3.1.  Scientific Rationale for Study Design   
Itacitinib  is a small molecule inhibitor of the JAK family of protein TY Ks, with selectivity for 
JAK1.  Members of the JAK family play an important role in signal transduction after cytokine 
and gro wth factor binding to their receptors .  Activated JAKs phosphorylate tyrosine residues on 
cytokine receptors and are the principal kinases associated with phosphorylation and activation 
of the STAT  pathway ( Murray 2007 ).  JAK1 plays a central role in a number of cytokine and 
growth factor â€“signaling pathways that, when dysregulated, can result in or contribute to disease 
and/or associated symptoms, such as CRS.  Excessive production of cytokines is associated with 
IEC therap y leading to CRS.  The therapeutic profile of itacitinib  encompasses multiple 
pathogenic cytok ines and not restricted to IL -6/IL-6R axis only (unlike, eg, tocilizumab).  
Efficacy is achieved by inhibiting cytokines derived from T -cells and monocyte /macroph ages 
with high clinical relevance to CRS  pathogenesis.  Further more , the prevention benefit is 
achieved without broad cytokine immunosuppression  (eg, as demonstrated by unchanged IL -5 
levels ; Guschin et al 1995 ). 
In pr eclinical mouse models , itacitinib  was able to significantly reduce serum levels of many of 
the cytokines  implicated in CRS (i e, IL-6, IL -12, and IFN -Î³) in a dose -dependent manner.  As 
expected , itacitinib  did not have a significant effect on cytokines ind ependent of JAK -1 pathway 
(ie, IL-5).  As confirmatory experiments, itacitinib  was also able to s ignificantly and 
dose-dependently reduce serum levels of inflammatory cytokines in a therapeutic Con -A-induced 
CRS as well as in prophylactic and therapeutic C D3-induced CRS mouse models .  Importantly, 
in preclinical models where human CD19 -CAR -T cells were adoptively transferred into 
CD19+ tumor -bearing immunodeficient animals, itacitinib  does not affect the antitumor activity 
of CAR -T cells.  See Section  2.5 for preclinical summary . 
Incyte Corporation  Page 25 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Therefore, it is hypothesized that itacitinib  may provide selective coverage to prevent CRS and 
the downstream effects of neuro toxicities  unlike tocilizumab with broad IL -6 implications .  
2.3.2.  Justification for Dose , Part 1  
Itacitinib potently inhibits JAK1 (half maximal inhibitory concentration [IC 50] = 3.6  nM at 1  mM 
adenosine triphosphate concentration), with 22 - to > 500-fold selectivity over the other JAK 
family members, JAK2, JAK3, and TYK2.  It does not significantly inhibit (<  30% inhibition) a 
broad panel of approximately 60  other kinases.  Itacitinib is also potent (IC 50 values of 
approximately 10  nM to 350 nM) in cytokin e-driven cell -based assays.  This effect is not due to 
general cytotoxicity.  Itacitinib also inhibits the growth of the cytokine -dependent cell line 
INA-6.  Itacitinib potently inhibits the phosphorylation of STAT proteins and the production of 
proinflamm atory factors induced by other cytokines, such as IL -23 and IL -6 with IC 50 values of 
approximately 30  nM to 100  nM. 
In a pilot study with itacitinib for acute GVHD , 200 mg  QD and 300 mg QD doses were 
similarly efficacious ; therefore, p reclinical studies were performed using a 60 and 120 mg/kg 
BID dosing paradigm , which provides whole blood JAK1 IC 50 (141 nM) coverage for 4 and 
12 hours respectively.  This coverage would be similar to human 200 mg QD dosing JAK1 IC 50 
(6.5 to 10 hours).  The studies show ed that with a dose equivalent to 200 mg QD in humans, 
itacitinib significantly reduced CRS inflammation without nega tively impacting CAR -T function 
(see Section  2.5, Preclinical Summary).  
In conclusion, itacitinib  is a highly selective and potent inhibitor of the JAK STAT pathway.   
CAR -T cell expansion demonstrated a relationship to a Grade 3 CRS and ICAN S, but also to 
response ( Neelapu et al 2017 ).  It is our hypothesis th at by administering a dose of itacitinib  
200 mg QD for 3 days prior to IEC,  there will be adequate dampening of the cytokines  to prevent 
â‰¥ Grade 2 C RS and ICANS  without affecting the response rate of IEC therapy .  It is also 
hypothesized that by continuing treatment for 2 6 days after IEC therapy, the continued exposure 
to itacitinib will prevent â‰¥  Grade 2 CRS and ICANS.  Therefore, itacitinib  200 mg QD will be 
admin istered at Day â€“3 through Day 26. 
2.3.3.  Preliminary Results from Part 1  
As of the preplanned interim analysis data cutoff (08  JAN 2021), 26 participants were enrolled, 
25 participants had completed Day 28 (EOT visit), and 26 participants had completed Day 14.  
The primary intent of this analysis was to minimize unnecessary exposure to itacitinib in the 
event of futility of preventing CRS.  Of the 26 participants, 3 (11.5%) participants experienced 
CRS Grade 2, and there was no participant with â‰¥ Grade 3 CRS.  Two participants received 
tocilizumab for CRS Grade 1.  Five (19.2%) participants had â‰¥ Grade 2 ICANS.   Results from 
this interim analysis have shown itacitinib to be well -tolerated, with preliminary evidence of 
clinical activity for t he prevention of CRS and ICANS.  
A PK analysis was also performed, based on the interim data cutoff described above.   Exposures 
were generally similar in this patient population to those observed in other patient populations 
receiving the same dose at stead y state, 200  mg QD.  The exposure range for itacitinib when 
dosed with axicabtagen  ciloleucel or tisagenlecleucel are highly overlapping, although limited 
patients had received tisagenlecleucel.  At the time of this interim analysis there was no apparent 
Incyte Corporation  Page 26 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  exposure/response relationship between measures of exposure (ie , AUC, C max, and C min) and 
CRS or ICANS grade.  
2.3.4.  Rationale for Part 2  
An additional dosing regimen of itacitinib will be explored in an expanded, Part 2 , of the study 
based on the following rationale:  
â€¢ Although preliminary data from Part 1 are promising, target cove rage following 
200 mg QD is <  10 hours, suggesting BID dosing may offer greater  target coverage 
over 24 hours.  
â€¢ The dose of itacitinib 200 mg BID was selected for the Part 2 expansion, based on 
nonclinical experiments and using a population PK model.  Nonclinical experiments 
utilizing a dose which achieved a similar level of target coverage as itacitinib 200  mg 
QD i n humans, demonstrated that itacitinib does not impact CAR -T function.  
However, in vitro experiments showed that T-cell proliferation may be impacted at 
high concentrations  with continuous exposure  (ie, > 500 nM ; see Figure  4) which 
exceed those following 200 mg QD after protein binding adjustment.  Using a 
population PK model (DMB -20.40 ), the concentration -time profiles following 
200 mg BID were simulated.  Free concentrations are predicted to remain below 
500 nM in at least 95% of participants , while the target coverage is maintained for a 
vast majority of the BID dosing interval as compared to less than half of the QD 
dosing interval ( see Figure 3). 
Figure 3: Simulated Free Itacitinib Concentration -Time Profiles  
 
Blue  = 400 mg, Green = 200 mg, Black = 100 mg.  Solid  = QD, Dashed  = BID.  Dotted red  = 500 nM, Dotted purple  = 49 nM.   
Free concentrations are used to account for in vivo protein binding which was not present in the in vitro T -cell proliferation 
experiments.  The IC50 is also protein binding adjusted as it was  calculated using total plasma concentrations (141nM for total 
concentrations).  
Part 2 is a randomized,  placebo -controlled portion of the study to determine the efficacy and 
safety of itacitinib 200 mg BID.  Investigators and participants will be blinded.  Approximately 
46 participants treated with Yescarta for relapsed  or refractory large B-cell lymphoma or 
follicular lymphoma will be enrolled in Part 2 of the study.  Participants will be randomized in a 
1:1 ratio to receive either itacitinib or placebo.  The comparison to placebo is relevant to provide 
a well -controlled assessment of efficacy, and it is justified considering that there is no available 
drug ther apy to be used as a comparator.  

Incyte Corporation  Page 27 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  2.4. Benefit/Risk Assessment  
Adverse events that have been most freque ntly reported in at least 10% of participants receiving 
itacitinib  monotherapy include anemia, thrombocytopenia, diarrhea, nausea, fatigue, and upper 
respiratory tract infection.  
As a result of itacitinib -mediated immunomodulation, an increased incidence of infections could 
possibly occur with itacitinib  therapy.   Strict clinical monitoring is indicated to identify and treat 
infections in study participants  should they occur.  
Because of the potential for m yelosuppression, participant s will have hematologic parameters 
closely monitored during clinical studies.  At the investigator 's discretion, i f there are clinically 
relevant declines in hematology parameters, therapy may be interrupted until resolution or 
discontinuation.  As itacitinib  also has the potential to cause WBC  margination (ie, a transient 
decrease in ANC), assessment of hematology parameters should be performed before study 
treatment administration at all applicable study visits.  
As described pr eviously, murine models of JAK/STAT inhibition using itacitinib  have 
demonstrated that efficacy is achieved by inhibiting cytokines derived from T -cells and 
monocyte /macrophages with high clinical relevance to CRS pathogenesis.  Further, the 
prevention ben efit is achieved without broad cytokine immunosuppression .  To the extent that 
the thrombocytopenia and anemia observed with  other JAK inhibitors  reflect the inhibition of 
JAK2 -mediated erythropoiesis and thrombopoiesis, a selective JAK1 inhibitor would li kely be 
associated with a lower incidence of thrombocytopenia and anemia, while still resulting in a 
significant reduction in the production and the signaling of inflammatory and immune cytokines.  
The use of  a JAK 1 inhibitor to prevent CRS in the presence  of IEC therapy  administration is 
being tested for the first time in this clinical study and, therefore, any potential benefit is 
hypothesized based on preclinical s tudies.  As described in Section  2.5, preclinical data suggest 
that JAK STAT pathway may contribute to driving an increase in cytokine and growth factor 
signaling pathways ; thereby , inhib iting this pathway may prevent  CRS  with a downstream effect 
on neurotoxicities . 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of itacitinib  may be found in the  IB, Section  6 Reference Safety Informat ion (IB).  
Refer to the prescribing information for reference therapies of Kymriah  (2018 ), Yescarta  (2021 ), 
and Tecartus  (2020 ). 
2.5. Preclinical Summary  
The biochemical potency of itacitinib for the inhibition of human JAK1, JAK2, JAK3, and 
TYK2 was determined in enzymatic assays using a recombinant truncated form of each family 
member that contained the catalytic domain.  The ability o f itacitinib to block enzyme activity is 
reported as the concentration required for IC 50.  The average IC 50 values from multiple lots of 
itacitinib are indicated in Table  6.  Based on these data, itacitinib is a potent inhibitor of JAK1 
(IC 50 value = 3.2  Â± 2.2 nM), with 22 - to > 600-fold selectivity for the other JAK family 
members.  
Incyte Corporation  Page 28 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  6: Enzyme Inhibitory Activity of Itacitinib Against Different Members of the 
Human JAK Family  
Enzyme  IC50 
Mean  Â± SD (nM)a Number of Experiments  Fold Selectivity for JAK1  
JAK1  3.2 Â± 2.2 70 â€“ 
JAK2  71.6 Â± 32.0 68 22 
JAK3  > 2000  13 > 600  
TYK2  818 Â± 272 13 256 
a Assays were performed at 1 mM ATP concentration.  
Using similar assay conditions as the JAK biochemical assays (ie, 1 mM ATP), itacitinib was 
selective against a broad panel of additional kinases when tested at a concentration of 20 Î¼M.  
To study the effect of itacitinib  on CAR -T-cells expansion and cytolytic activity, Ganglioside  
GD2 specific CAR -T-cells were expanded in vitro  with anti -CD3/anti -CD28 coated beads in the 
presence of increasing itacitinib  concentrations, ranging from 100 to 500 nM.  As shown in 
Figure  4 when compared with the DMSO control, itacitinib  at 100  to 250 nM did not have a  
significant effect on CD3/CD28 -induced expansion of human T -cells, while 500 nM was enough 
to block CAR -T cell proliferation.  Importantly, GD2 -CAR -T-cells expanded in the pres ence of 
low (100 and 250 nM) itacitinib  concentrations were able to efficiently lyse GD2 -expressing 
tumor cells .  As shown in Figure  4 itacitinib ï‚£ 250 n M did not significantly impair CAR -T 
expansion, while ï‚³ 500 nM reduced the proliferative response.  Importantly, GD2 -CAR -T cells 
expanded in the presence of itacitinib concentrations ï‚£ 250 nM were able to efficiently lyse 
GD2  expressing tu mor cells.  
Figure  4: Effect of Increasing Itacitinib Concentrations on CAR -T Cell Proliferation 
and Effector Function  
 
Flow cytometry quantification of GD2 -CAR -T expansion expanded with increasing concentrations of itacitinib.   T cells CAR -T 
cells were expanded using anti -CD3/anti -CD28 coated beads  and proliferation measured every other day by flow cytometry (left 
panel).   GD2 -CAR -T cells were expanded in the presence of different itacitinib concentrations and then co -cultured with  
luciferase expressing SY5Y neuroblastoma cells (GD -2+).  Lytic activity of GD2 -CAR -T cells was determined by measuring 
luciferase activity.  As internal  control, lytic activity of non transduced T cells was also measured (background dotted line ; right 
panel).  
To further elucidate the potential impact of itacitinib on CAR -T cell function we adoptively 
transferred  human CD19 -CAR -T cells into immunodeficient recipient mice that  were harboring 

Incyte Corporation  Page 29 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  CD19 expressing NAMALWA human lymphoma cells.  As shown in  Figure  5, animals that 
received non -tumor targeting T cells (control)  reached humane endpoint by Day 21.  In contrast, 
vehicle -treated mice receiving an adopti ve transfer of CAR -T cells demonstrated a significant 
delay in mortality ( p = 0.0014).  Daily itacitinib dosing (120 mg/kg) achieved a significant 
survival improvement (p  = 0.0003) compared with control T cells and was similar to vehicle 
dosed CAR -T-cell a nimals (p  = 01860), thus indicating that itacitinib treatment did  not 
negatively impact the anti tumor activity of CAR -T cells  (see Figure  5). 
Figure  5: Itacitinib Effect on CD19 -CAR -T Cells In Vivo Antitumor Activity  
 
Immunodeficient mice were inoculated with CD19+ human lymphoma NAMALWA -luciferase cell line and treatment initiated 
5 days later.  Animal received BID doses of itacitinib or vehicle for 10 days.  At Day 8, post-tumor injection, animals received an 
adoptive transfer of either control T cells o r CD19 -CAR -T cells.  N = 12 animals per group.   Left panel represents a 
Kaplan -Meier curve for the overall survival of the mice.   In vivo bioluminescence imaging of representative animals challenged 
with luciferase -expressing NAMALWA lymphoma cells and different treatments over time (right p anel).  Data representative of 
2 independent experiments.  
Finally, the potent ial of itacitinib to reduce CRS -related cytokines produced by human 
CD19 -CAR -T cells was explored.  As a positive control tocilizumab was utilized.  In vitro, 
CD19 -CAR -T cells were expanded in the presence of increasing concentrations of itacitinib 
(100 or 300 nM) or tocilizumab (20, 100 , or 200 Î¼g/mL).  After a 3 -day expansion in the 
presence of drug, CAR -T cells were co -cultured with CD19 expressing NAMALWA tumor 
target cells and 6 hours later supernatants collected.   As shown in  Figure  6, itacitinib , but not 
tocilizumab, significantly reduced the levels of multiple inflammatory cytokines ( ie, IL-2, IFN -Î³, 
IL-6, or IL -8).  As background control, non transduced T cells unable to target NAMALWA 
tumor target cells demonstrated no meaningful cytokines response.  

Incyte Corporation  Page 30 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Figure  6: Itacitinib Effect on CAR -T Cells Production of Inflammatory Cytokines  
 
ELISA = enzyme -linked immunosorbent assay.  
CD19 -CAR -T cells were expanded with either itacitinib or tocilizumab (anti â€“IL-6 receptor).  Three days later , they were co -
cultured with CD -19+ lymphoma cells (E :T ratio = 2.5:1) for 6 hours and cytokines measured in the supernatant by ELISA.  Data 
represent mean Â± SEM, and p -values were calculated by 2-way ANOVA.  
** p<0.01, *** p<0.001 versus vehicle control.  Data representative of 2 independent experiments.  
2.5.1.  Preclinical Summary Conclusions  
Itacitinib potently inhibits JAK1 (IC 50 = 3.2 nM), with 22 - to > 600 -fold s electivity for the other 
JAK family members, JAK2, JAK3 , and TYK2 . 
Itacitinib concentrations relevant to the in vitro IC 50 did not adversely a ffect the proliferation or 
antitumor killing capacity of human CAR -T cells.  In an in vivo model of adoptively tra nsferred 
human CD19 -CAR -T cells into CD19+ NAMALWA bearing mice, itacitinib did not reduce the 
antitumor activity.  Furthermore, itacitinib did not reduce in vitro antigen driven proliferation of 
OVA -specific mouse T cells.  Consistent with this observatio n, itacitinib in vivo  did not  affect 
antitumor  T cell activity against an OVA -expressing tumor cell line within an immune 
competent recipient mouse.  
In 2 in vivo mouse models ( concanavalin A  and anti -CD3) of T -cell hyperactivation resulting in 
cytokine storm, itacitinib reduced serum levels of CRS -related cytokines in a dose -dependent 
manner.  
Finally, in an in vitro model, itacitinib , but not tocilizumab, significantly reduced CRS -related 
cytokines produced by CD19 -CAR -T cells ( PRECLIN -19.16.1 ). 

Incyte Corporation  Page 31 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  3. OBJECTIVES AND ENDPOINTS  
Table  7 presents the objectives and endpoints  for Part 1 and Part 2 , supporting selection of 
optima l dosing/schedule of itacitinib for subsequent trials . 
Table  7: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the efficacy of itacitinib as a 
preventative treatment for CRS associated with 
IEC therapy . Efficacy , as determined by the proportion of 
participants who develop â‰¥ Grade 2 CRS by 
Day 14, using  ASBMT CRS Consensus Grading.  
Secondary  
To evaluate the proportion of participants with 
ICANS regardless of CRS, after IEC therapy.  Incidence  and severity of ICANS , as determined 
by the proportion of participants with ICANS by 
Day 28, after IEC therapy using  the ICANS 
Consensus Grading.  
To evaluate the onset and episode of ICANS 
using  the ICANS Consensus Grading, regardless 
of CRS, by Day 28.  Time to onset and d uration of ICANS using  the 
ICANS Consensus Grading, regardless of CRS, 
by Day 28.  
To evaluate the duration of all grade s of CRS, by 
Day 28.  Time to onset and d uration of all grade s of CRS 
by Day 28 using  ASBMT CRS Consensus 
Grading.  
To evaluate the proportion of participants  who 
develop any  grade of CRS within 48 hours after 
IEC therapy.  Proportion  of participants with any  grade of CRS 
at 48 hours, after IEC therapy using  ASBMT CRS 
Consensus Grading.  
To evaluate the proportion of participants  who 
develop â‰¥  Grade 2 CRS by Day 28 of 
administration after first IEC therapy.  Proportion of participants with â‰¥  Grade 2 CRS by 
Day 28, after first IEC therapy.  
To characterize the safety of itacitinib, before and 
after IEC th erapy, excluding  CRS and ICANS.  Safety of itacitinib assessed by the incidence of all 
AEs except CRS and ICANS, by collecting 
laboratory data, performing physical 
examinations, and collecting vital signs beginning 
at Day â€“3 and through the duration of safety 
follow -up. 
â‰¥ Grade 3 Cytopenias  ongoing by Day 30.  
To evaluate the number of and length of hospita l 
admissions for CRS and ICANS.  Number of hospital admissions and duration of 
stay for participants with CRS and/or ICANS by 
EOS . 
To assess intervention for CRS and ICANS . Proportion of participants who were treated with 
tocilizumab for CRS.  
Proportion of participants requiring more than 1 
dose of dexamethasone (or equivalent) for 
ICANS.  
Incyte Corporation  Page 32 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  7: Objectives and Endpoints (Continued)  
4. STUDY DESIGN  
4.1. Overall Design  
This is  a 2-part study desig ned to assess the safety and efficacy of oral administration of 
itacitinib for the prevention of CRS  in male or female participants aged 12 years or older and 
who are planning to receive IEC therapy  for any approved hematologic indication.  
Part 1:  Approximately 62 parti cipants will be administered  itacitinib 200mg QD  (open label) .  
The study population will include participants receiving any approved IEC for an approved 
indication.  
Part 2:  Approximately 46 participants will be randomized to 1 of 2 cohorts  (~23 evaluable  
participants in each cohort) .  Participants will be randomized 1:1 to receive either itacitinib 
200 mg BID  or placebo .  The study population will include participants who are receiving 
Yescarta for relapsed  or refractory  large  B-cell lymphoma  or follicular lymphoma .  Investigators 
and participants will be blinded.  The sp onsor will be unblinded  in order to ensure ongoing safety 
monitoring for the itacitinib 200 mg BID cohort . 
This study includes a 14-day screening period  after apheresis .  Apheresis will be per institutional 
standard of care.  Conditioning chemotherapy will  be administered at the discretion of the 
investigator.  
Participants will be administered study treatment  beginning at Day â€“3 to Day â€“1 before  IEC 
infusion.  IEC therapy will be administered on D ay 0 along with study treatment .  Participants 
will continue to receive  study treatment through D ay 26 to complete a 30-day study treatment 
period . 
During the treatment period, Protocol -defined assessments will be conducted on Day â€“3, Day â€“1, 
Day 0 (IEC infusion day), Day 1, Day 3, Day 5, Day 7, Day 14, D ay 21, and D ay 28.  Restaging 

Incyte Corporation  Page 33 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  of hematologic disease will be conducted per institutional guidelines .  Completers are defined as 
participants who complete 30 days  of study treatment administration  (Day â€“3 to Day 26) .  An 
EOT assessment will be conducted at Day 28 Â± 2 days.   Additional post -therapy follow -up visits 
will be conducted 30 days after the last dose of  study treatment and 90 and 180 days after IEC 
infusion . 
Safety will be monitored beginning at screening and will continue through to a 30 -day 
post-treatment safety follow -up visit.  Collection of 6 -month survival  follow -up will be required 
and recorded in the electronic database.  End of study is met at the  6-month survival follow -up. 
Hematologic disease assessments sho uld be cond ucted as indicated in the SoA.  The date of the 
assessment as well as the results should be recorded in the eCRF.  
An interim analysis for CRS futility will be conducted when 24 participants are treated with IEC 
therapy , in Part 1,  and complete  the Day 28 (EOT) visit.  The study may be stopped for futility at 
the interim analysis if the conditional power based on interim results is lower than 20%, which is 
equivalent to more than 17 out of 24 participants experiencing â‰¥ Grade 2 CRS by Day 14.  
See Section  6.1 for full  itacitinib  administration information  and to Table  3, Schedule of 
Assessments in Section  1, Protocol Summary.   Decentralized assessments ar e acceptable ; 
however , principal investigator  oversight is required.  
4.2. Overall Study Duration  
The study begins when the first participant signs the ICF.  The end of the study is expected to 
occur when the last participant reaches  their 6 -month follow -up visi t. 
Completers (of treatment) are defined as participants who complete 30 days  of study treatment 
administration  (Day â€“3 to Day 26) .  A participant is considered to have completed the study if 
he/she has completed all periods  of the study including the 6-month follow -up for which a 
disease assessment  is required.  
4.3. Study Termination  
The investigator retains the right to terminate study participation at any time, according to the 
terms specified in the study contract .  The investigator is to notify the I RB in writing of the 
study 's completion or early termination, send a copy of the notification to the sponsor or 
sponsor 's designee, and retain 1  copy for the site study regulatory file.  
The sponsor may terminate the study electively, if required by regulat ory decision or upon 
advice  of the internal DSMB .  If the study is terminated prematurely, the sponsor will notify the 
investigators, the IRBs, and regulatory bodies of the decision and reason for termination of the 
study .  The DSMB will recommend terminat ion of the study if warranted, as described in 
Section  11.7. 
Incyte Corporation  Page 34 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  5. STUDY POPULATION  
Deviations from eligibility criteria are not allowed because they can potentially jeopardize the 
scientific integrity of the study, regulatory acceptability, and/or participa nt safety .  Therefore, 
adherence to the criteria as specified in the Protocol is essential .  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or 
exemptions, are not permitted.  
5.1. Inclusion Crit eria 
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Part 1:  Male or female, 12 years of age or older.  The participant (or legally acceptable 
representative for participants <  18 years of age ) has the ab ility to comprehend and 
provides written informed consent for the study.  
Note:  The participants who are < 18 years of age will have a parent or legal guardian 
able to give written informed consent and assent (as appropriate) according to 
institutional standards and to comply with all study visits and procedures.  
Part 2:  Male or female, 18 years of age or older.   
2. Eligible to receive an IEC therapy  that is approved by the health authority in the country 
where the study is being conducted , for hematologic indications.  
Part 1:  Eligible to receive any IEC therapy for any approved indication . 
Part 2:   Eligib le to receive Yescarta for relapsed or refractory large B -cell lymphoma 
or follicular lymphoma . 
3. ECOG performance status  0 to 1. 
4. Willingness t o avoid pregnancy or fathering children based on the criteria below.  
a. Men must agree to take appropriate precautions to avoid fathering children (with at 
least 99% certainty ) from screening through safety follow -up and must refrain from 
donating sperm durin g this period .  Permitted methods that are at least 99% effective 
in preventing pregnancy ( see Appendix  A) should be communicated to the 
participant s and their understanding confirmed.   
b. Wom en of childbearing potential must have a negative serum pregnancy test at 
screening and before the first dos e on Day 1 and must  agree to take appropriate 
precautions to avoid pregnancy (with at least 99% certainty) from screening through 
safety follow -up.  Permitted methods that are at least 99% effective in preventing 
pregnancy (see Appendix  A) should be communicated to the participant s and their 
understanding confirmed.  
c. Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or 
bilateral oophorectomy OR â‰¥ 12 months of amenorrhea ) are eligible.  
Incyte Corporation  Page 35 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Evidence of active uncontrolled/untreated infection (viral, bacterial, fungal, 
opportunis tic) of any origin . 
2. Evidence of active HBV or HCV infection as defined in Section  8.3.5.2 . 
3. Known human immunodeficiency virus . 
4. Active acute or chronic GVHD requiring system ic therapy.  
5. Concurrent use of chronic systemic steroids or immunosuppressant medications.   
6. Known hypersensitivity or severe reaction to itacitinib , similar compounds, or excipients 
of itacitinib . 
7. Any unresolved toxicity â‰¥ Grade 2 (except stable Grade 2 peripheral neuropathy or 
alopecia) from previous anticancer therapy.  
8. Participants with a known  history or prior diagnosis of immunologic or 
inflammatory/autoimmune disease affecting the CNS , and unrelated to their disease 
under study or previous treatment.  
9. Clinically significant or uncontrolled cardiac disease, including unstable angina, acute 
myoc ardial infarction within 6 months from Day â€“3 of itacitinib  administration, New 
York Heart Association Class III or IV congestive heart failure, and circulatory collapse 
requiring vasopressor or inotropic support.  Participants with a rrhythmias that are no t 
stable on a medical management program within 2 weeks of induction Day â€“3 are also 
excluded . 
10. Central nervous system status:  
a. Acute lymphoblastic leukemia p articipants with the following CNS status are eligible 
only in the absence of neurologic symptoms  suggestive of CNS leukemia, such as 
cranial nerve palsy:  
âˆ’ CNS1, defined as absence of blasts in CSF on cytospin preparation, regardless of 
the number of WBCs . 
âˆ’ CNS2, defined as presence of <  0.5 Ã— 109/L WBCs in CSF and cytospin positive 
for blasts, or >  5/Î¼L WBCs , but negative by Steinherz/Bleyer algorithm:  
â–ª CNS2a:  < 1.0 Ã— 109/L RBCs; <  0.5 Ã— 109/L WBCs and cytospin positive for 
blasts.  
â–ª CNS2b:  â‰¥ 1.0 Ã— 109/L RBCs; <  0.5 Ã— 109/L WBCs and cytospin positive for 
blasts.  
â–ª CNS2c:  â‰¥ 1.0 Ã— 109/L RBCs ; â‰¥ 0.5 Ã— 109/L WBCs and cytospin positive for 
blast , but negative by Steinherz/Bleyer algorithm.  
Incyte Corporation  Page 36 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  b. Diffuse large B -cell lymphoma  participants:  Participants must have no signs or 
symptoms of CNS disease or detectable evidence of CNS disease; participants who 
have  been previously treated for CNS  disease but have no evidence of disea se at 
screening are eligible.  
11. Participants who are currently breastfeeding.  
12. Receipt of a prior investigational study agent within 4 weeks before  screening visit.  
Note:  Participants who have received anti -CD19 IEC therapy  on a study where cell 
infusion occurred greater than 4 weeks before the screening visit are NOT excluded.  
13. Any condition that would, in the investigator 's judgment, interfere with full participation 
in the study, includi ng administration of itacitinib  and attending required study visits (if 
outpatient); pose a significant risk to the participant; or interfere with interpretation of 
study data.  
14. Inability of the participant to swallow and retain oral medication.  
15. Participant s with laboratory values at screening defined in Table  8. 
Table  8: Exclusionary Laboratory Values  
Laboratory Parameter  Exclusion Criterion  
Hematology  
a Platelets  â‰¤ 10 Ã— 109/L 
b Hemoglobin  â‰¤ 8 g/dL 
Hepatic  
e ALT  â‰¥ 2.5  Ã— ULN  for age, > 5 Ã— ULN in the presence of liver metastases  
f AST  â‰¥ 2.5  Ã— ULN  for age, > 5 Ã— ULN in the presence of liver metastases  
g Total  bilirubin  > 1.5 Ã— ULN or > 3 Ã— ULN in the presence of documented Gilbert 's 
syndrome (unconjugated hyperbilirubinemia)  
Renal  
h Creatinine  clearance  Participants â‰¥ 18 years of age :  â‰¤ 50 mL/minute based on Cockcroft -
Gault formula . 
Participants < 18 years of age :  GFR  < 15 based on revised Schwartz 
formula  2009 . 
The cutoffs for mild, moderate, and severe renal insufficiency based on 
Cockcroft -Gault are 60 -90 mL/min, 30 -59 mL/min, and 0 -29 mL/min, 
respectively.  
Note:  Creatinine clearance necessitates a 24 -hour urine sample 
before the blood draw to calculate .  An estimated value is acceptable.  
Cardiopulmonary  
i Cardiac LVEF  â‰¤ 40% confirmed by ECHO/multigated analysis  
j Adequate pulmonary function  â‰¥ Grade 2 dyspnea and â‰¥  Grade 2 hypoxia  
5.3. Lifestyle Considerations  
Participants should be instructed to refrain from the consumption of pomegranates or 
pomegranate juice and grapefruit and grapefruit juice , as these are known to inhibit CYP3A 
enzymes and may increase the exposure to itacitinib . 
Incyte Corporation  Page 37 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  5.4. Screen Failu res 
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently entered in the study  within the 14-day screening period .  At a minimum, the 
following information must be collected and entered into t he eCRF :  demography, screen failure 
details, and eligibility criteria.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened 1 time if the investigator believes that there has been a change in eligibility status . 
Participants who rescreen must be assigned a new participant number, must be re -consented to 
participate in the study, and must repeat all screening procedures  (laboratory assessments do not 
need to be repea ted if done within 3 days of rescreening) . 
Tests with results that fail eligibility requirements may be repeated once during screening if the 
investigator believes the result to be in error.  
5.5. Replacement of Participants  
Participants who do not meet the eligibility requirements of the s tudy may be replaced.  
6. STUDY TREATMENT  
6.1. Study Treatment  Administered  
Table  9 presents the study treatment information.  
Table  9: Study Treatment Information  
 Study Treatment  
Study treatment name:  Part 1:  Itacitinib  (all participants)  
Part 2:  Itacitinib or placebo  
Dosage formulation:  Sustained release  
Unit dose strength(s)/dosage 
level(s):  100 mg tablets  
Part 1:  200 mg QD  
Part 2:  200 mg BID  or placebo  
Route of  administration:  Oral 
Administration instructions:  Study treatment should be taken with water and regardless of food.  
 
 
Packaging and labeling:  Study treatment  will be provided to sites in high -density polyethylene 
bottles as applicable by Incyte.  No  preparation is required.  
Each bottle will be labeled as per country requirement . 
Storage:  Study treatment should be stored at ambient condit ions 
(15Â°C -30Â°C or 59Â°F -86Â°F) as per the  IB.  

Incyte Corporation  Page 38 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  6.1.1.  Study Treatment Preparation , Handling , and Accountability  
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment s received and any discrepancies are reported and 
resolved before use of the study treatmen t. 
Only participants enrolled  in the study may receive study treatment , and only authorized site 
staff may supply or administer study treatmen t.  All study treatment  must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the  
labeled storage conditions with access limited to the investigator and authorized site staff.  
The investigator  (or designee)  is responsible for study treatment  accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records) .  Inventory and 
accountability records must be maintained and readily available for inspection by the study 
monitor and are open to inspection at any time by any applicable regulatory authorities .  The 
investigator or designee must mai ntain records that document:  
â€¢ Delivery of study treatment to the study site.  
â€¢ Inventory of study treatment at the site.  
â€¢ Participant use of the study treatment including pill  counts from each supply 
dispensed.  
â€¢ Return of study treatment to the investigator or designee by participants . 
The investigational product must be used only in accordance with the Protocol .  The investigator 
will also maintain records adequately documenting that the participants were provided the 
specified itacitinib .  These records should  include dates, quantities, and any available batch or 
serial numbers or unique code numbers assigned to the investigational product and study 
participants.  
Completed accountability records will be archived by the site .  The investigator or designee will 
be expected to collect and retain all used, unused, and partially used containers of itacitinib  until 
verified by the study monitor (unless otherwise agreed to by the sponsor) .  At the conclusion of 
the study, the investigator or designee will oversee shipm ent of any remaining itacitinib  back to 
the sponsor or its designee for destruction according to institutional SOPs.  If local procedures 
mandate on -site destruction of investigational supply, the site should (where local procedures 
allow) maintain the inv estigational supply until the study monitor inspects the accountability 
records in order to evaluate compliance and accuracy of accountability by the investigative site .  
At sites where the itacitinib  is destroyed before monitor inspection, the monitors re ly on 
documentation of destruction per the site SOP.  
Further guidance and information for the final disposition of unused study treatment s are 
provided in the  Pharmacy  Manual.  
See Appendix  C for instructions for participants for handling itacitinib.  
6.1.2.  Study Treatment Compliance  
Compliance with study treatment should be emphasized to the participant by the site personnel, 
and appropriate steps should be taken to optimize compliance during the study.  Compliance 
with study treatment will be calculated by the sponsor based on the drug accountability or dose 
Incyte Corporation  Page 39 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  administration record documented by the site staff and monitored by the s ponsor/designee.  
Participants will be instructed to bring all tablets with them to the study visits in order for site 
personnel to conduct tablet counts to assess itacitinib  accountability.  The drug accountability 
documentation or dose administration rec ord will be used by the sponsor to calculate treatment 
compliance.  
6.1.3.  Dose Modifica tions for Itacitinib  
Part 1  
This Protocol includes a treatment regimen which is defined as  follows :  itacitinib  beginning on 
Day â€“3 of itacitinib  200 mg QD through D ay 26. 
If a dose reduction of itacitinib  from 200 mg QD to 100 mg QD, outside of the treatment 
regimen, is warranted in the judgment of the principal investigator , and in consultation with the 
medical monitor (whenever possible), while taking into account either the relatedness of an AE 
to the study treatment and/or the participant 's underlying condition, then the dose reduction may 
be allowed.  There will be no further d ose reductions below 100 mg QD.  
If a dose  interruption  is needed, the sponsor/medical monitor should be contacted.  
Safety concerns should be discussed with the sponsor immediately upon occurre nce or awareness 
to determine whether  the participant should continue or discontinue study treatment.  
Part 2  
The treatment regimen in Part 2 is defined as 200  mg BID or placebo . 
If a dose reduction is required , from 200 mg BID to 100 mg BID, th e participant may take 
1 tablet of study treatment instead of 2 tablets.  
6.1.4.  Criteria for Permanent Discontinuation of Study Treatment  
The occurrence of unacceptable toxicity not caused by the underlying disease will require that 
study treatment be permanently discontinued .  See Section  7.1.2  for discontinuation procedures.  
Unacceptable toxicity is defined as follows:  
â€¢ Occurrence of an AE that is related to study treatment that, in the judgment of the 
investigator or the sponsor 's medical monitor, compromises the participant 's ability to  
continue study -specific procedures or is considered to not be in the participant 's best 
interest.  
6.2. Immune Effector Cell Therapy  
In Part 1 p articipants will receive IEC therapy  that is approved by the health authority in the 
country where the study is being  conducted  for any a pproved hematologic indication.  
In Part 2 par ticipants will receive Yescarta . 
IEC therapy will be supplied by the site and administered per standard of care.  If conditioning 
chemotherapy is required, this will also be administered per standard of care at the discretion of 
the investigator.  
Incyte Corporation  Page 40 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  6.3. Measures to Minimize Bias:  Randomization and Blinding  
In Part 2,  participants will be randomized to receive either itaciti nib 200  mg BID or placebo.  
Investigators and participants will be blinded.  
6.4. Concomitant Medications  and Procedures  
All concomitant medications and treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF .  Any 
prior medication received up to 30 days before the first dose of study treatment and 30 days after 
the last dose of study treatment will be recorded in the eCRF .  Any addition, deletion, or change 
in the dose  of these medications will also be recorded .  Concomitant medications administ ered 
up to 30 days after the last dose of study treatment for an SAE should be recorded for SAEs as 
defined in Section  9. 
6.4.1.  Permitted Medications  and Procedures  
Concomitant treatments and/or procedures that are required to manage a participant 's medical 
condition during the study will also be recorded in the eCRF . 
6.4.2.  Restricted Medications  and Procedures  
The following medications have restrictions on use during the treatment period of the study:  
â€¢ Aspirin in doses exceeding 125  mg per day is not permitted.  Low -dose aspirin 
(â‰¤ 125 mg per day) is permitted unless clinic ally contraindicated.  
â€¢ Coadministration with strong CYP3A  inhibitors . 
âˆ’ If the participant 's medical condition requires treatment with posaconazole, 
itraconazole, voriconazole, mibefradil, or clarithromycin , a dose reduction of 
itacitinib  is recommended  (see below) , as strong  CYP3A inhibitors have been 
shown to increase exposure to itacitinib  (see Appendix  B). 
Part 1 dose reduction:  Itacitinib 200 mg QD may be reduced to 100 mg QD . 
Part 2 dose reduction:   Itacitinib 200 mg BID (or Placebo) may be reduced to 
100 mg BID or p lacebo.  
âˆ’ The sponsor me dical monitor may be consulted for advice when CYP3A 
inhibitors are considered . 
â€¢ If concomitant administration of an anticoagulant/antiplatelet medication is indicated, 
then caution and enhanced monitoring is required.  History of thrombocytopenia 
should be  a factor in the choice of anticoagulant and dose.  
â€¢ Tocilizumab and/or corticosteroids for CRS Grade 1 is not allowed.  However, 
tocilizumab may be given as rescue medication for CRS Grade 1 if no improvement 
is observed within 72 hours from onset , and the participant's medical condition 
requires intervention per investigator judg ment . 
Incyte Corporation  Page 41 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  6.4.3.  Prohibited Medications  and Procedures  
The following medications are prohibited during the treatment period of the study:  
â€¢ Concomitant use of another JAK inhibitor.  
â€¢ Initiating therapy with an investigational medication unless otherwise approved by 
the medical monitor , such as anakinra in the treatment of CRS . 
â€¢ Coadministration with strong CYP3A  inducers.  The FDA DDI website provides the 
most current list of strong CYP3A  inducers .  
6.5. Treatment After the End of the Study  
There will be no further treatment of itacitinib  after Day 26. 
7. DISCONTINUATION OF S TUDY TREATMENT  AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
7.1.1.  Reasons for Discontinuation  
Participants  must  be withdrawn from study treatment for the following reasons:  
â€¢ The participant becomes pregnant.  
â€¢ Consent is withdrawn .   
Note:  Consent withdrawn means that the participant has explicitly indicated that they 
do not want to be followed any longer; in this case no further data, except data in 
public domain, may be solicited from or collected on the participant .  Participants 
may choose to discontinue study treatment and remain in the study to be followed for 
progression and survival.  
â€¢ Further participati on would be injurious to the participant 's health or well -being, in 
the investigator 's medical judgment.  
â€¢ Unacceptable tox icity.  
â€¢ The study is terminated by the sponsor.  
â€¢ The study is terminated by the loc al health authority , IRB, or IEC . 
A participant  may be discontinued from study treatment as follows:  
â€¢ If, during the course of the study, a participant is found not to have met eligibility 
criteria, the medical monitor, in collaboration with the investigator, will determine 
whether the participant should be wi thdrawn from study  treatment . 
â€¢ If a participant is noncompliant with study procedures or itacitinib /treatment  
administration in the investigator 's opinion, the sponsor should be consulted for 
instruction on handling the participant.  
Incyte Corporation  Page 42 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  7.1.2.  Discontinuation Procedur es 
In the event that the decision is made to permanently discontinue the study treatment  before 
Day 28, the EOT visit should be conducted .  Reasonable efforts should be made to have the 
participant return for a 30-day safet y follow -up visit .  These visits are described in Table  3.  The 
last date of the last dose of itacitinib  and the reason for discontinuation of study treatment will be 
recorded in the eCRF.  
If a participant is discontinued from study treatment:  
â€¢ The s tudy monitor or sponsor must be notified.  
â€¢ The reason(s) for withdrawal must be documented in the participant 's medical record 
and the primary reason for withdrawal must be included in the eCRF.  
â€¢ The E OT visit should be performed.  
â€¢ The date of the E OT visit should be recorded in the IRT.  
â€¢ Participants must be followed for safety until the time of the 30-day follow -up visit or 
until itacitinib â€“related toxicities resolve, return to baseline, or are deemed 
irreversible, whichever is longest.  
If the participant di scontinues study treatment and actively withdraws consent for collection of 
follow -up data (safety  follow -up or survival follow -up), then no additional data collection should 
occur; however, participants will have the option of withdrawing consent for stud y treatment but 
continuing in the follow -up period of the study .   
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for  safety, behavioral, compliance, or 
administrative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withd raws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
See Table  3 for data to be collected at the time of s tudy discontinuation and follow -up and for 
any further evaluations that need to be completed.  
7.3. Lost to Follow -Up 
A participant  will be considered lost to follow -up if he /she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site . 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
â€¢ The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
Incyte Corporation  Page 43 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study.  
â€¢ Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant 's last known mailing a ddress 
or local equivalent methods) .  These contact attempts should be documented in the 
participant 's medical record.  
â€¢ Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study . 
7.4. Study Treatment Completion  
A completer is defined as a participant who completed itacitinib administration  for the 30 -day 
treatment period (Day â€“3 to Day 26) . 
Incyte Corporation  Page 44 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  8. STUDY ASSESSMENTS AN D PROCEDURES  
8.1. Administrative and General Procedures  
8.1.1.  Informed Consent Process  
â€¢ The investigator or their representative will explain the nature of the study to the 
participant or their legally authorized representative and answer all questions 
regarding the study.  
âˆ’ Informed consent must be obtained before any study -related procedures are 
conducted, unless otherwise specified by the Protocol.  
âˆ’ Informed consent must be obtained using the IRB/IEC -approved version in a 
language that is native and understandable to the participant. An ICF template 
will be provided by the sponsor or its designee. The sponsor or it s designee must 
review and acknowledge the site -specific changes to the ICF template. The ICF 
must include a statement that the sponsor or its designee and regulatory 
authorities have direct access to participant records.  
âˆ’ The ICF must contain all required elements including optional 
samples/procedures (eg, optional biopsy) and describe the nature, scope, and 
possible consequences of the study in a form understandable to the study 
participant.  
â€¢ Participants must be informed that their participation is volunta ry.  Participants or 
their legally authorized representative will be required to sign a statement of informed 
consent that meets the applicable requirements and regulations within the USA as 
well as the IRB or study center.  
â€¢ The participant must be informed  that his/her personal study -related data will be used 
by the sponsor in accordance with local data protection laws.  The level of disclosure 
must also be explained to the participant.  
â€¢ The participant must be informed that his/her medical records may be ex amined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
sponsor, by appropriate IRB  members, and by inspectors from regulatory authorities.  
â€¢ The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must 
also sign the ICF.  
â€¢ Participants must provide consent to the most current version of the ICF(s ) during 
their participation in the study.  
â€¢ A copy of the ICF(s) must be provided to the participant or the participant 's legally 
authorized representative.  
â€¢ Participants who are rescreened are required to sign a new ICF.  
Incyte Corporation  Page 45 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  8.1.2.  Screening Procedures  
Screening is th e interval between signing the ICF and the day the participant is enrolled in the 
study , which is Day â€“3, pre-IEC.  Assessments that are required to demonstrate eligibility may 
be performed over the course of 1  or more days during the screening process.  
Procedures conducted as part of the participant 's routine clinical management (eg, blood count, 
imaging study) and obtained before signing of informed consent may be used for screening or 
baseline purposes provided the procedure meets the Protocol -defined criteria and has been 
performed in the timeframe of the study (ie, within 14  days of Day â€“3) unless otherwise 
specified .  For participants who are enroll ed in the study, information associated with eligibility 
requirements must be entered into the appropri ate eCRF pages , as an example, information about 
apheresis and conditioning chemo therapy , if applicable . 
Results from the screening visit evaluations will be reviewed to confirm eligibility before 
enrollment  or the administration of itacitinib .  Individual s who do not meet the criteria for 
participation in this study (screen failure) may be rescreened 1 time if the investigator believes 
that there has been a change in eligibility status .  Tests with results that fail eligibility 
requirements may be repeated  once during screening if the investigator believes the results to be 
in error .  For screening assessments that are repeated, the most recent available result before 
dosing itacitinib  will be used to determine eligibility . 
See Section s 5.4 and 5.5 for information regarding screen failures and rep lacement of 
participants, respectively.  
8.1.3.  Interactive Response Technology Procedure  
Each participant will be identified in the study by a participant ID number, which is a 
combination of the site ID and participant number .  Site staff should contact the IRT to obtain the 
participant ID number during screening .  Upon determining that the participant is eligible for 
enrollment , the IRT will be contact ed in order to register the participant for enrollment.  The IRT 
will contacted again at EOT.   Additional details are provided in the IRT manual.  
8.1.4.  Distribution of Reminder Cards  
Participants will be provided with a reminder card at each visit .  The reminder card will indicate 
the date/time of the next visit and will also remind the participant that they should  not take their 
morning dose of itacitinib /treatment   
 
 
8.1.5.  Demography and Medical History  
8.1.5.1.  Demographics and General Medical History  
Demographic data and general medica l history will be collected at screening  by the investigator 
or qualified designe e and will include year of birth/age , race, ethnicity, medical and surgical 
history, and current illnesses.  Medical history will include relevant medical or surgical treatmen t 
within the last 2 years that are considered to be clinically significant by the investigator.  

Incyte Corporation  Page 46 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  8.1.5.2.  Disease Characteristics and Treatment History  
A disease -targeted medical and treatment history will be collected at screening .  Details 
regarding the participant 's hematologic disease  under study, including date of diagnosis, initial 
and current cancer stage, tumor histology, and relevant disease characteristics, and prior 
treatments, including systemic treatments, radiation, and surgical procedures, wi ll be recorded . 
8.2. Efficacy and Endpoint Assessments  
8.2.1.  CRS  Status  
The ASBMT /ASTCT  CRS Consensus Grading Criteria will be used to assess CRS  (see 
Table  10).  CRS status will be captured on a CRS form within the eCRF.   Fever should be 
monitored, once IEC is administered through EOT.  If a participant has a fever, CRS should be 
graded and recorded in the eCRF.  
Table  10: ASBM T CRS Consensus  Grading  
CRS Parameter  Grade 1  Grade 2  Grade 3  Grade 4  
Fevera Temperature â‰¥  38Â°C  Temperature â‰¥  38Â°C  Temperature â‰¥  38Â°C  Temperature â‰¥  38Â°C  
With Either:  
Hypotension  None  Not requiring 
vasopressors  Requiring one 
vasopressor with or 
without vasopressin  Requiring multiple 
vasopressors 
(excluding 
vasopressin)  
And/Orb 
Hypoxia  None  Requiring low -flow 
nasal cannulac or 
blow -by Requiring high -flow 
nasal cannulac, 
facemask, non -
rebreather mask, or 
Venturi mask  Requiring positive 
pressure (eg , CPAP, 
BiPAP, intubation , 
mechanical 
ventilation)  
BiPAP = bi -level positive airway pressure; CPAP = continuous positive airway pressure.  
Note:  Organ toxicities associated with CRS may be graded according to CTCAE v5.0 but they do not influence CRS grading.  
a Fever is defined as temperature â‰¥  38Â°C not attributable to any other cause.  In participants  who have CRS and then receive 
antipyretics or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS 
severity.  In  this case, CRS grading is driven  by hypotension and/or hypoxia.  
b CRS grade is determined by the more severe event:  hypotension or hypoxia not attributable to any other cause.  For example, a 
participant  with temperature of 39.5Â°C, hypotension requiring one vasopressor and hypoxia requiring low flow nasal cannula is 
classified as having Grade 3  CRS.  
c Low-flow nasal cannula is defined as oxygen delivered at â‰¤  6 liters/minute.  Low -flow also includes blow -by oxygen delivery, 
sometimes used in pediatrics.  High -flow nasal cannula is defined as oxygen delivered at >  6 liters/minute.  
Source:  Lee et al 201 8 and Neelapu 2019 . 
8.2.2.  ICANS Status  
The ASBMT /ASTCT  ICANS Consensus Grading Criteria will be u sed to assess neurotoxicity 
(see Table  11).  ICANS status will be captured on an ICANS form within the eCRF.   The 
participant should be monitored for signs and symptoms of ICANS, if symptoms develop at any 
point after IEC, the participant  should be evaluated  in order to determine an ICANS grade and 
the details recorded in the eCRF.  
Incyte Corporation  Page 47 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  11: Encephalopathy Assessment Tool for Grading of Immune Effector  
Cellâ€“Associated Neurotoxicity Syndrome  
Neurotoxicity Domain  Command  Total Points  
Orientation  Orient to year, month, city and hospital  4 points (1 point each)  
Naming  Name 3 objects (point to 3 objects, such as a 
clock, pen, and button)  3 points (1 point each)  
Following Commands  Follow commands such as:   show me 2 fingers or 
close your eyes and stick out your tongue  1 point in total  
Writing  Ability to write a standard sentence such as:  Our 
national bird i s the bald eagle . 1 point in total  
Attention  Count backwards from 100 by ten; eg,  100, 90, 80  1 point in total  
Score 10:  No Impairment  
Score 7 -9:  Grade 1 ICANS  
Score 3 -6:  Grade 2 ICANS  
Score 0 -2:  Grade 3 ICANS  
Score 0 due to participant  unarousable and unable to perform  ICE assessment:  Grade 4 ICANS  
Grading of IEC therapy related encephalopathy syndrome (ICANS) will be assessed using the 
ASBMT Consensus Grading for Neurological Toxicity Associated With Immune Effector Cells 
(see Table  12). 
Incyte Corporation  Page 48 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  12: ASBMT Immune Effector Cell â€“Associated Neurotoxicity Syndrome 
Consensus Grading  
Neurotoxicity 
Domain  Grade 1  Grade 2  Grade 3  Grade 4  
ICE scorea 7-9 3-6 0-2 0 (participant  is 
unarousable  and unable 
to perform ICE) . 
Depressed level of 
consciousnessb Awakens 
spontaneously . Awakens to 
voice . Awakens only to tactile 
stimulus . Participant  is 
unarousable  or requires 
vigorous or repetitive 
tactile stimuli to around.   
Stupor or coma.  
Seizure  N/A N/A Any clinical seizure focal or 
generalize d that resolves 
rapidly; or non convulsive 
seizures on EEG that 
resolve with intervention . Life-threatening 
prolonged seizure 
(> 5 min); or repetitive 
clinical or electrical 
seizures without  return 
to baseline in between.  
Motor findingsc N/A N/A N/A Deep focal motor 
weakness such as 
hemiparesis or 
paraparesis.  
Raised 
ICP/ cerebral 
edema  N/A N/A Focal/local edema on 
neuroimagingd. Diffuse cerebral edema 
on neuroimaging; 
decerebrate or 
decorticate posturing; or 
cranial nerve VI palsy; 
or papilledema; or 
Cushing 's triad.  
ICE = immune effector cell â€“associated encephalopathy; ICP = intracranial pressure; EEG  = electroencephalogram.  
Note:  ICANS grade is determined by the most severe event (ICE score, level of consciousness, seizure, motor findings, and 
raised ICP/cerebral ed ema) not attributable to any other cause.  For example, a participant  with an ICE score of 3 who has a 
generalized seizure is classified as having Grade 3 ICANS.  
a A participant  with an ICE score of 0 may be classified as having Grade 3 ICANS if the participant  is awake with global 
aphasia.  But a participant  with an ICE score of 0 may be classified as having Grade 4 ICANS if the participant  is unarousable.  
b Depressed level of consciousness should be attributable to no other cause (eg , no sedating medication).  
c Tremors and myoclonus associated with IEC therap ies may be graded according to CTCAE v5.0 but they do not influence 
ICANS grading.  
d Intracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excl uded from 
ICANS grading.  It may be graded according to CTCAE v5.0.  
If the participant  has no impairment (ICE score of 10), then Grade 0 may be entered in the EDC  
for ICANS Grade . 
8.2.3.  Lee's CRS Revised Grading System  
The following grading information will be c ollected in the eCRF for purp oses of historical 
comparison  of previous captured published grading scales.  
Incyte Corporation  Page 49 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  13: Lee CRS Revised Grading System  
Grade  Toxicity  
Grade 1  Symptoms are not life -threatening and require symptomatic treatment only, eg, fever, 
nausea, fatigue, headache, myalgias, malaise . 
Grade 2  Symptoms require and res pond to moderate intervention : 
Oxygen requirement <  40%; or h ypotension responsive to fluids or low dose of 
1 vasopressor or Grade 2 organ  toxicity . 
Grade 3  Symptoms  require and respond to aggressive intervention : 
Oxygen requirement â‰¥  40% or hypotension requiring high dose or multiple vasopressors or 
Grade 3 organ toxicity or Grade 4 transaminitis . 
Grade 4  Life-threatening symptoms  such as requirement for ventilator support or Grade 4 organ 
toxicity (excluding transaminitis) . 
Grade 5  Death . 
Source:  Lee et al  2014 . 
8.3. Safety Assessments  
The following safety assessments will be collected according to the SoA ( see Table  3) unless 
directed otherwise.  
8.3.1.  Adverse Events  
Adverse events will be monitored from the time the participant signs the ICF  until at le ast 
30 days after the last dose of study treatment .  Adverse events that begin or worsen after 
informed consent should be recorded on the Adverse Events Form in the eCRF  regardless of the 
assumption of a causal relationship with the itacitinib .  Conditions that were already present at 
the time of informed consent should be recorded on the Medical History Form in the eCRF .  
Adverse events (including laboratory abnormalities that constitute AEs) should be described 
using a diagnosis whenever possibl e rather than by individual underlying signs and symptoms.  
Adverse events will be reported by the participant (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally authorized representative) .  The investigator and any 
qualified des ignees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following  up on AEs that are serious, 
that are considered related to the study treatment /procedures, or that caused the participant to 
discontinue the  itacitinib .  Care will be taken not to introduce bias when detecting AEs and/or 
SAEs .  Open -ended and nonleading verbal questioning of the participant, such as "How are you 
feeling? " is the preferred method to inquire abo ut AE  occurrences .  Adverse events may also be 
detected when they are volunteered by the participant  during the screening process or between 
visits, or through physical examination s, laboratory test s, or other assessments .  The definition, 
reporting, and r ecording requirements for AEs are described in Section  9. 
All SAEs will be recorded and reported to the sponsor or designee within 24 hours .  The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available.  
Incyte Corporation  Page 50 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts .  All SAEs  will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to fo llow-up (as defined in Section  7.3). 
8.3.2.  Physical Examinations  
Physical examinations must be performed by a medically qualified individual , such as a licen sed 
physician, physician 's assistant, or an advanced registered nurse practitioner, as local law 
permits .  Height will be assessed at screening only.  Weight should be assessed at each 
timepoint.  Abnormalities identified after t he first dose of itacitinib  constitute an AE if they are 
considered clinically meaningful, induce clinical signs or symptoms, require concomitant 
therapy, or require changes in study  itacitinib .  Investigators should pay special attention to 
clinical signs related to previous seriou s illnesses.  
During the study, participants will be assessed by the investigator or medically qualified 
designee per institutional standard of care.  These assessments should be an evaluation as 
indicated by participant symptoms, AEs, or other findings and  documented on the AE eCRF.  
8.3.3.  Vital Signs  and Temperature Monitoring  
Vitals will i nclude blood pressure, pulse, respiratory rate, and body temperature .  Blood pressure 
and pulse will be taken with the participant  in the recumbent, semi recumbent , or sitting position 
after 5  minutes of rest .  Abnormal vital sign results identified after the first dose of study 
treatment constitute an AE if they are considered clinically meaningful, induce clinical signs or 
symptoms, require concomitant therapy, or require chan ges in itacitinib . 
Temperature should be monitored  starting on Day âˆ’3 through EOT ( Day 28  Â± 2 days) .  Any 
temperature â‰¥  38Â°C should  be documented for CRS grading.  
The participant will be encouraged to use a TempTraqÂ® device as a tool for temperature 
monitoring.  Additional instructions regarding the TempTraq device will be provided separately.  
If a participant in unable to wear the device at any point during the treatment period, this will not 
be considered a Protoco l deviation . 
8.3.4.  Eastern Cooperative Oncology Group Performance Status  
The ECOG performance status will be assessed as indicated in Table  3 according to th e criteria 
in Table  14. 
Incyte Corporation  Page 51 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  14: Eastern Cooperative Oncology Group Performance Status Scoring  
Grade  Performance Status  
0 Fully active, able to carry on all predisease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work.  
2 Ambulatory and capable of all self -care but unable to carry out any work activities.  Up and 
about more than 50% of waking hours.  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours.  
4 Completely disabled.  Cannot carry on any self -care.  Totally confined to bed or chair.  
5 Dead.  
Source:  Oken et al 1982 . 
8.3.5.  Local Laboratory Assessments  
See Table  15 for the list of clinical laboratory tests to be performed and the SoA (see Table  3) for 
the timing and frequency .  A certified laboratory local to the investigative site will perform all 
clinical l aboratory assessments except as identified in  Table  16 and Table  17. 
The investigative site will enter the laboratory results and laboratory nor mal ranges into the 
eCRF .  Additional testing may be required by the sponsor based on emerging safety data .  
Additional tests may also be performed if clinically indicated.  
Clinically significant abnormal laboratory findings are those that are not associat ed with the 
underlying disease, unless judged by the investigator to be more severe than expected for the 
participant 's condition .  All laboratory tests with values considered clinically significantly 
abnormal during participation in the study or within 30 days after the last dose of itacitinib  
should be repeated until the values return to normal or baseline or are no longer considered 
clinically significant by the investigator or medical monitor.   See Appendix  D for management 
of potential Hy 's Law cases.  
Screening laboratory assessments must be performed within 7 days of Day â€“3.  If performed 
more than 3 days before Day â€“3, then the tests m ust be rep eated and eligibility confirmed before 
study trea tment administration on Day â€“3.  Laboratory samples collected on study Day â€“3 must 
be performed before study treatment administration . 
Incyte Corporation  Page 52 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  15: Required Laboratory Analytes  
Chemistr y Hematology  Urinalysis With 
Microscopic 
Examination  Serology  Coagulation  
Albumin  
Alkaline phosphatase  
ALT  
AST  
Amylase  
Bicarbonate or CO 2 
Blood urea nitrogen or 
urea 
Calcium  
Chloride  
Creatinine  
Glucose  
Lactate dehydrogenase  
Lipase  
Phosphate  
Potassium  
Sodium  
Total bilirubin  
Direct bilirubin (if total 
bilirubin is elevated above 
ULN)  
Total protein  
Uric acid  Complete blood 
count, including:  
Hemoglobin  
Hematocrit  
Platelet count  
Red blood cell count  
White blood cell 
count  
 
Differential c ount, 
including:  
Basophils  
Eosinophils  
Lymphocytes  
Monocytes  
Neutrophils  
 
Absolute values must 
be provided for:  
WBC differential 
laboratory results  Color and 
appearance  
pH and specific 
gravity  
Bilirubin  
Glucose  
Ketones  
Leukocytes  
Nitrite  
Occult blood  
Protein  Hepatitis B surface 
antigen  
Hepatitis B surface 
antigen antibody  
Hepatitis B core 
antibody  
HBV -DNA  
HCV antibody  
HCV -RNA  PT 
PTT or aPTT  
INR 
Lipid Panel  Ferritin Level  Pregnancy Testing  
Total cholesterol  
Triglycerides  
LDL  
HDL  Ferritin level  Required for female 
participants of 
childbearing 
potential.  
See Section  8.3.5.1 . C-Reactive Protein  
CRP  
aPTT = (activated ) partial thromboplastin  time; HDL = high -density lipoprotein;  INR = international normalized ratio; 
LDL  = low-density lipoprotein; PT = prothrombin time  
Note:  Additional tests may be required, as agreed upon by the investigator and sponsor, based on emerging safety data.  
8.3.5.1.  Pregnancy Testing  
A serum pregnancy test will be required for all women of childbearing potential during 
screening , the Day 28 visit, and the 30-day follow -up visit .  A urine  or serum  pregnancy  test may 
be collected on Day â€“3 before  administration of itacitinib .  If the participant is going to hospice , 
the Day 28 pregnancy test may be omitted .  Additionally, urine p regnancy tests should  be 
performed as medically indicated (eg, in case of loss of menstrual cycle, when pregnancy is 
suspected) .  If a urine pregnancy test is positive, the results should be confirmed with a serum 
pregnancy test.  
If the serum pregnancy test is  negative after a urine test was positive, t he investigator will assess 
the potential benefit/risk to the participant and determine whether it is in the participant 's best 
interest to resume itacitinib  and continue participation in the study.  
If a pregnancy is confirmed by a serum pregnancy test, see Section  9.7 for reporting 
requirements.  
Incyte Corporation  Page 53 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  8.3.5.2.  Serology  
If hepatitis status is obtained within 60 days  of the screening visit, that result may be used for 
this study.  HBV/HCV testing should be repeated if there is any clinical suspicion of active 
hepatitis during screening.  If hepatitis status is not known , hepatitis screening assessments will 
be perform ed at the screening visit to rule out hepatitis infection; required analytes are shown in 
Table  15.  Generally, hepatitis tests should be performed earl y in the screening process due to the 
length of time needed to obtain the results .  Additional tests may be performed if clinically 
indicated.   Hepatitis PCR assays only required if serology  is positive.   HBV -DNA does not need 
to be performed if the anti-HBs is the only positive result (indicating immunity due to 
vaccination).  
The eligibility of any participant with positive viremia (eg,  PCR assay targets detected) must be 
discussed with the medical monitor before participant enrollment.  
8.4. Hematologic D isease Status  
Participants are expected to have an objective assessment of disease status using PET/CT /MRI  or 
bone marrow biopsy according to the institution 's standard of care and the participant 's 
hematologic disease .  The results of these assessments will be record ed in the eCRF at screening, 
Day 28, restaging of disease , and at post-treatment follow -up visits (90 day s and 180 days 
post-IEC treatment).  If a disease assessment occurs at a different timepoint, per institutional 
guidelines , then this is acceptable.   Any hematologic disease  assessment s that are conducted 
during the study should be captured in the eCRF.   
A bone marrow assessment performed within 180 days of Day âˆ’3 can be used for the purpose of 
this study.  
Additional information with regar d to response  criteria that should be used for lymphoma is 
provided in Appendix  E.  
Additional information with regard to response  criteria that shoul d be used for ALL  is provided 
in Appendix  F. 
 
 

Incyte Corporation  Page 54 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  

Incyte Corporation  Page 55 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  8.7. Unscheduled Visits  
Unscheduled study visits may occur at any time during the study if medically wa rranted.  Data 
from all assessments performed at unscheduled visits must be recorded in the eCRF.  
8.8. End of Treatment  
Per the Protocol, Day 26 is the last expected day of study treatment administration.  An EOT 
visit will be conducted at Day 28 (Â± 2 days).  
If the participant discontinues study treatment before Day 26, the EOT visit will still be 
conducted.  
Unless the participant withdraws consent, all study assessments should continue to be performed 
and captured in the eCRF.  
8.9. Follow -Up 
8.9.1.  Safety Follow -Up 
The safety follow -up period is the interval between the  last dose of study treatment and the 
scheduled safety follow-up visit, which will  occur approximately 30 days after the  last dose of 
itacitinib .  Adverse events and SAEs must be reported up until 1) at least 30  days after the last 
dose of study treatment  or 2) until toxicities resolve, return to baseline, or are deemed 
irreversible, whichever is longer .  Reasonable efforts should be made to have the participant 
return for the 30-day safety follow -up vi sit and report any AEs that may occur during this period .  
If the participant cannot return to the site for the 30-day safety follow -up visit (eg, lives far 
away), the participant should be contacted by telephone for assessment of AEs and SAEs .  This 
conta ct should be documented in the source  and eCRF . 

Incyte Corporation  Page 56 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  8.9.2.  Hematologic Disease Follow -Up 
All participants are expected to be followed , and hematologic disease status should be collected,  
until EOS  (Day 180) , unless informed consent is withdrawn . 
During the follow -up period , hematologic disease assessments should be conducted at Day 28, 
restaging of disease, Day 90 , and Day  180.  However, if disease assessments are performed at 
different timepoints, based on institutional guidelines , then this is acceptable.  All disea se 
assessments should be captured in the eCRF.   For additional guidance, see Section  8.4, 
Appendix  E, and Appendix  F. 
8.9.3.  Electrocardiograms  and Echocardiogram s 
A 12-lead ECG will be obtained  as outlined in the SoA (see  Table  3) using an ECG machine that 
automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.  Al l 
12-lead ECGs will be performed with the participant in a recumbent or semirecumbent position 
after 5  minutes of rest.  
The 12 -lead ECGs will be interpreted by the investigator at the site to be used for immediate 
participant management.  Additional 12 -lead ECGs may be performed as clinically indicated to 
manage participant  safety.  
The decision to include or exclude a participant or withdraw a participant from the study 
treatment based on an ECG flagged as "Abnormal, Clinically Significant " is the responsibility of 
the investigator, in consultation with the sponsor 's medical monitor, as appropriate.  Clinically 
notable abnormalities that are considered clinically significant in the judgment of the investigator 
are to be reported as AEs.  
An a ssessment of LVEF will be performed locally by ECHO  or multigated analysis to determine 
the cardiac function of the participant  and to confirm study eligibility.  If cardiac functional 
status is obtained within 60 days of the screening visit, for the purpo ses of IEC therapy, that 
result may be used for this study.  
8.9.4.  Survival Follow -Up 
Participants will be contacted by telephone, email, or with a visit to assess for survival.  All 
participants will be followed for survival until EOS  (Day 180), unless informed consent is 
withdrawn.  
8.10. End of Study  
End of study is defined as partic ipants who complete Day 180  or who withdraw their informed 
consent.  
The EOS will be recorded in the eCRF and will mark the end of the study for the participant.  
Incyte Corporation  Page 57 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  9. ADVERSE EVENTS:  DEFINITIONS AND PROC EDURES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  
9.1. Definition of A dverse Event 
Adverse Event Definition  
â€¢ An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or 
not considered drug -related.  
â€¢ An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study 
treatment.  
Events Meeting  the A dverse Event Definition  
â€¢ Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from 
baseline  (Day â€“3), considered clinically significant in the medical and scientific judgment of the 
investigator (ie,  not related to progression of underlying disea se). 
â€¢ Abnormal  laboratory test results constitute an AE if they are considered clinically meaningful, induce 
clinical signs or symptoms, require concomitant therapy, or require changes in study treatment .  
Whenever possible, a diagnosis (eg, anemia, thrombo cytopenia) should be recorded in the eCRF 
rather than the abnormal lab result (eg, low hemoglobin, platelet count decreased).  
â€¢ Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the  condition.  
â€¢ New conditions detected or diagnosed after study treatment administration even though they may 
have been present before the start of the study.  
â€¢ Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
â€¢ Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication .  Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose ta ken with possible suicidal/self -harming intent .  Such overdoses s hould be 
reported regardless of sequelae.  
â€¢ "Lack of efficacy " or "failure of expected pharmacological action " per se will not be reported as an 
AE or SAE .  Such instances will be captured in the efficacy assessments .  However, the signs, 
symptoms, and/or cl inical sequelae resulting from lack of efficacy will be reported as an AE or SAE 
if they fulfil l the definition of an AE or SAE .  As an example, CRS or neurotoxicities will not be 
recorded as lack of efficacy but will be recorded as AE s/SAE s as appropriate.  
Events NOT  Meeting the A dverse Event Definition  
â€¢ Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by the investigator to be more severe than 
expected for the participant 's condition.  
â€¢ The disease/disorder being studied or expected progression, signs, or s ymptoms of the 
disease/disorder being stu died, unless more severe than expected for the participant 's condition  or 
considered to be treatment -related by the investigator . 
â€¢ Efficacy endpoints as outlined in Section  3 will not be reported as AE/SAEs, specifically, any event 
that is related to disease progression of the cancer under study.  Unblinded aggregated efficacy 
endpoint events and safety data will be monitored to ensure the safety of the participant s in the study .  
Any suspected endpoint that upon review is not progression of the cancer under study will be 
forwarded to Incyte Pharmac ovigilance as a SAE within 24 hours of determination that the event is 
not progression of the cancer under study.  
Incyte Corporation  Page 58 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  â€¢ Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to the 
procedure is the AE  if it occurred after signing  informed consent .  If present before entering the 
study, the condition  should be captured as medical history.  
â€¢ Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospital).  
â€¢ Anticipated day -to-day fluc tuations of pre -existing disease(s) or condition(s) present or detected at 
the start of the study that do not worsen.  
9.2. Definition of S erious Adverse Event 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease).  
A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose:  
a.  Results in death  
b.  Is life -threatening  
The term 'life-threatening ' in the definition of 'serious ' refers to an adverse drug experience that places 
the participant , in the opinion of the initial reporter, at immediate risk of death from the adverse 
experience as it occurred.  This does not include an adverse drug experience that, had it occurred in a 
more severe form, might have caused death . 
c.  Requires inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the participant has been detained (usually involving at least an 
overnight stay) at the hospital  or emergency ward for observation and/or treatment that would not have 
been appropriate in the physician 's office or  outpatient setting .  Complications that occur during 
hospitalization are AEs .  If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious .  When in doubt as to whether "hospitalization " occurred or was necessar y, the AE 
should be considered serious.  
Hospitalization for elective treatment or planned surgery (eg, stent replacement, hip surgery) is not 
considered an SAE.  
Hospitalization for medical interventions in which no unfavorable medical occurrence occurred 
(ie, elective procedures or routine medical visits) is not considered an SAE.  
d.  Results in persistent or significant disability/incapacity  
â€¢ The term disability means a substantial disruption of a person 's ability to conduct normal life 
functions.  
â€¢ This defini tion is not intended to include experiences of relatively minor medical significance , such 
as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, 
sprained ankle) , that may interfere with or prevent everyday life functi ons but do not constitute a 
substantial disruption.  
e.  Is a congenital anomaly/birth defect  
Incyte Corporation  Page 59 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  f. Other situations  (Important Medical Event)  
An event that may not result in death, be immediately life -threatening, or require hospitalization, but 
may be considered serious when, based on appropriate medical judgment, the event may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes listed in 
the above definition.   Examples of such events include invasive or malignant cancers  (excluding the 
disease[s] under study in oncology protocols) , intensive treatment in an emergency department  or at 
home for allergic bronchospasm, blood dyscrasias , or convulsions that do not result in hospitalization, 
or development of drug dependency or drug abuse.  
9.3. Recording and Follow -Up of Adverse Events and/or S erious Adverse 
Events 
Adverse Event and S erious Advers e Event Recording  
â€¢ An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event  Form in the eCRF .  Conditions that were present at the time informed consent was 
given should be recorded on the Medical History Form in the eCRF.  
â€¢ When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospital progress notes, laboratory reports, and diagnostics reports) related to the event.  
â€¢ The investigator (or delegate) will then recor d all relevant AE/SAE information in the eCRF.  
â€¢ It is not acceptable for the investigator to send photocopies of the participant 's medical records in 
lieu of completing  the AE eCRF page.  
â€¢ There may be instances when copies of medical records for certain cases are requested .  In this case, 
all participant identifiers, with the exception of the participant number, will be redacted on the copies 
of the medical records before submission.  
â€¢ The investigator will attempt to establish a diagnosis of the event base d on signs, symptoms, and/or 
other clinical information .  Whenever possible, the diagnosis (not the individual signs/symptoms) 
will be documented as the AE/SAE .  When a clear diagnosis cannot be identified, each sign or 
symptom should be reported as a sepa rate AE /SAE . 
To the extent possible, each AE /SAE  should be evaluated to determine:  
â€¢ The severity grade (CTCAE Grade 1 to 5).  See below for further instructions on the assessment of 
intensity.  
â€¢ Whether there is at least a reasonable possibility that the AE i s related to the study treatment  
(including itacitinib (s) and/or reference therapy) :  suspected (yes) or not suspected (no) .  See below 
for further instructions on the assessment of causality.  
â€¢ The start and end dates, unless unresolved at final follow -up. 
â€¢ The action taken with regard to study treatment  as a result of the AE/SAE (s) and/or reference 
therapy . 
â€¢ The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
â€¢ The serio usness, as per the SAE definition provided in Section  9.2. 
â€¢ The action taken with regard to the event .  Note:  If an AE is treated with a concomitant medication 
or nondrug therapy, this action should be recorded on Adverse Event Form and the treatmen t should 
be specified on the appropriate eCRF (eg, Prior/Concomitant Medications , Procedures and Non -Drug 
Therapy ). 
Incyte Corporation  Page 60 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0  Grades 1 through 5 .  For the purposes of this 
Protocol, CRS and ICAN events will be graded per ASBMT CRS Consensus Grading and ASBMT 
ICANs Co nsensus Grading, respectively.  If an event is not classified by CTCAE, the severity of the 
AE will be graded according to the scale below to estimate the grade of severity:  
The investigator will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
â€¢ Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment  
not indic ated.  
â€¢ Grade 2:   Moderate; minimal, local, or noninvasive treatment  indicated; limiting age appropriate 
activities of daily living.  
â€¢ Grade 3:   Severe or medical ly significant but not immediately life -threatening; hospitalization or 
prolongation of hospitaliz ation indicated; disabling; limiting self -care activities of daily living.  
â€¢ Grade 4:   Life-threatening consequences; urgent treatment  indicated.  
â€¢ Grade 5:   Fatal.  
Assessment of Causality  
â€¢ The investigator is obligated to assess the relationship between study treatment and each occurrence 
of each AE/SAE .  If reference therapy is used in combination with an Incyte itacitinib , the 
relationship to each itacitinib /reference therapy  must be assessed (ie,  for the Incyte product(s) and for 
the other product (s) that is used in combination with the Incyte product) .  If appropriate, the 
relationship to the combination may be assessed as well.  
â€¢ A "reasonable possibility " of a relationship conveys that there are facts, evidence, and/or arguments 
to suggest a causal relationship, rather than that a relationship cannot be ruled out.  
â€¢ The investigator will use clinical judgment to determine the relationship.  
â€¢ The investigator w ill also consult the Reference Safety Information in the IB and/or Product 
Information, for marketed products, in his/her assessment.  
â€¢ Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well 
as the temporal re lationship of the event to study treatment administration , will be considered and 
investigated.  
â€¢ For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
â€¢ With regard to assessing causality of SAEs:  
âˆ’ There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report .  However,  the causality assessment is one of the criteria 
used when determining regul atory reporting requirements.  Therefore,  it is very important that 
the investigator always make an assessment of causality for every event before the initial 
transmission of the SAE.  
âˆ’ The investigator may change his/her opinion of causality in light of fol low-up information and 
send a follow -up SAE report with the updated causality assessment.  
Incyte Corporation  Page 61 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Follow -Up of A dverse Events and S erious Adverse Events 
â€¢ The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by the sponsor to elucidate the nature 
and/or causality of the AE or SAE as fully as possible .  This may include additional laboratory tests 
or investigations, histopathological examinations, or consultation with other health care 
professionals.  
â€¢ New or updated information will be recorded in the originally completed eCRF.  
â€¢ Any updated SAE data will be subm itted to the sponsor (or designee) within 24  hours of receipt of 
the information.  
â€¢ Once an AE is detected, it should be followed until it has resolved or until it is judged to be 
permanent; assessment should be made at each visit (or more frequently if nece ssary) of any changes 
in severity, the suspected relationship to the study treatment , the interventions required to treat the 
event, and the outcome.  
â€¢ When the severity of an AE changes over time for a reporting period (eg, between visits), each 
change in s everity will be reported as a separate AE until the event resolves . 
9.4. Reporting of S erious Adverse Events 
Regardless of suspected causality (eg, relationship to study treatment [s], reference therapy,  or 
study procedure [s]), all SAEs occurring after the participant has signed the ICF through the last 
study vis it or at least 30  days after the last dose of study treatment must be reported to the 
sponsor (or designee) within 24 hours  of learning of its occurrence, unless otherwise specified 
by the Protocol .  If an SAE occurs more than 30 days after the last dose of study treatment, it is 
only required to be reported if it is considered to be related to study treatment .  The investigator 
will submit any updated SAE data to the sponsor (or designee) within 24 ho urs of it being 
available . 
Investigators are not obligated to actively seek SAE information after conclusion of the study 
participation .  However, if the investigator learns of any SAE, including a death, at any time after 
a participant has been discharged  from the study, and he/she considers the event to be reasonably 
related to the study treatment or study participation, the investigator must notify the sponsor (or 
designee) within 24 hours of becoming aware of the event . 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts .  All SAEs,  will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (see Section  7.3). 
Prompt notification by the investigator to the sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
treatment under clinical investigation are met . 
If the SAE is not documented in the IB for the study treatment  (new occurrence) and is thought 
to be related to the study treatment , the sponsor or its designee may urgently require further 
information from the investigator for reporting to health authorities .  The sponsor or its designee 
may need to issue an Investigator Notification to inform all investigators involved in any study 
with the same drug that this SAE has been reported .  Suspected Unexpected Serious Adverse 
Reactions will be collected and reported to the competent  authorities and relevant ethics 
Incyte Corporation  Page 62 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  committees in accordance with Directive 2001/20/EC, or as per national regulatory  requirements 
in participating countries.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation .  The 
sponsor will comply with c ountry -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB, and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions  
according to local regulatory requirem ents and sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB and will notify the IRB , if appropriate accord ing to local requirements.  
Serious Adverse Event Reporting  
â€¢ Information about all SAEs is collected and recorded on the Adverse Event Form in the eCRF . 
â€¢ The investigator must report within 24 hours of learning of its occurrence any SAE by completing 
the Ser ious Adverse Event Report Form in English . 
â€¢ Follow -up information is recorded on an amended or new Serious Adverse Event  Report Form, with 
an indication that it is follow -up to the previously reported SAE and the date of the original report .  
The follow -up report should include information that was not provided on the previous Serious 
Adverse Event  Report Form, such as the outcome of the event (eg, resolved or ongoing), treatment 
provided, action taken with study treatment  because of the SAE (eg, dose reduce d, interrupted, or 
discontinued), or participant  disposition (eg, continued or withdrew from study participation) .  Each 
recurrence, complication, or progression of the original event should be reported as follow -up to that 
event, regardless of when it occ urs. 
â€¢ Contacts for SAE reporting can be found in  the investigator site file.  
9.5. Adverse Events of Special Interest  
Not applicable.  
9.6. Emergency Unblinding of Treatment Assignment  
In a medical emergency, if knowledge of the treatment assignment is necessary to determine 
optimal medical management of the participant , the procedure for emergency unblinding is 
provided in the Pharmacy Manual .  This option may be used only if the partic ipant's well -being 
requires the investigator to be aware of the participant's treatment assignment.  If a participant's 
treatment assignment must be  unblinded, the sponsor must be notified immediately by telephone.  
Incyte Corporation  Page 63 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  9.7. Pregnancy  
Pregnancy, in and of itself, is  not regarded as an AE unless there is suspicion that study treatment  
may have interfered with the effectiveness of a contraceptive medication or method .  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study 
treatment , the following procedures should be followed in order to ensure safety:  
â€¢ The study treatment  must be discontinued immediately.  
â€¢ The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy.  
Data on fetal outcome are collected for regulatory reporting and drug safety evaluation .  
Follow -up should be conducted for each pregnancy to determine outcome, including spontaneous 
or voluntary termination, details o f the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by following until the first 
well-baby visit .  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by the investigator to the sponsor or its designee .  Pregnancy follow -up information should be 
recorded on the same form and should include an assessment of the possible causal relationship 
to the sponsor 's study treatment  to any pregnancy outcome, as well as follow -up to the first 
well-baby visit or the duration specified in local regulations, whichever is later .  Refer to the 
Incyte Reference Guide for Completing the Clinical Trial Pregnancy Form.  
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event  Report Form and submitted to the sponsor or designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs  (if occurrin g in the study participant) and 
must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant 's partner, the event should be reported to the sponsor on the Clinical Trial 
Pregnancy Form. 
9.8. Warnings and Precautions  
Special warnings or precautions for the study treatment  derived from safety information 
collected by the sponsor or its designee, are prese nted in the Section  2.4.  Additional safety 
information collected between IB updates will be communicated in the form of Investigator 
Notifications .  Any important new safety information should be discussed with the  participant 
during the study, as necessary .  If new significant risks are identified, they will be added to the 
ICF. 
9.9. Product Complaints  
The sponsor collects product complaints on itacitinib  and drug delivery systems used in clinical 
studies in order to en sure the safety of study participants, monitor quality, and facilitate process 
and product improvements.  
All product complaints associated with material packaged, labeled, and released by the sponsor 
or its designee will be reported to the sponsor .  All product complaints associated with other 
study material will be reported directly to the respective manufacturer.  
Incyte Corporation  Page 64 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  The investigator or his/her designee is responsible for reporting a complete description of the 
product complaint via email or other written c ommunication to the sponsor contact or respective 
manufacturer as noted in the packaging information .  Any AE associated with a product 
complaint should be recorded as described in Section  9.3. 
If the investigator is asked to return the product for investigation, he/she will return a copy of the 
product complaint communication with the product.  
9.10. Treatment of Overdose  
For this study, any dose of greater th an 400 mg wit hin a 24 -hour time period will be considered 
an overdose.  
In the event of an overdose, the investigator or treating physician  should:  
â€¢ Contact the medical monitor immediately.  
â€¢ Closely monitor the participant for any AE/SAE and laboratory abnorm alities for at 
least 2 days . 
  
 
 
â€¢ Document the quantity of the excess dose as well as the duration of the overdose in 
the eCRF.  
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with  the medical monitor based on the clinical evaluation  of the participant.  

Incyte Corporation  Page 65 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  10. STATISTICS  
10.1. Sample Size Determination  
Part 1  is a single -arm open -label study.  The sample size calculation is based on the primary 
endpoint of â‰¥ Grade 2 CRS rate by Day 1 4.  It was considered that 60% â‰¥  Grade 2 CRS by 
Day 14 is clinica lly relevant in this setting.  Based on a target rate of 60%, a sample size of 
62 will provide 90% power to exclude a higher limit of 79% of a 2-sided 95% CI.  The sample 
size calculation is based on an efficacy evaluable analysis set (see  Section  10.2 for definition).  
Table  18 represents CRS Rat es and CIs for a sample size of 62 . 
Table  18: CRS Rates and 95% Confidence Intervals  
Sample Size  Number of CRS  CRS Rate (%)  95% Confidence Interval (%)  
62 36 58.1 44.8, 70.5  
62 38 61.3 48.1, 73.4  
62 40 64.5 51.3, 76.3 
62 42 67.7 54.7, 79.1  
62 44 71.0 58.1, 81.8  
Part 2  is a randomized expansion of the study; it acitinib 200 mg BID versus placebo.  
As in Part 1, the primary endpoint is Grade â‰¥ 2 CRS ra te by Day 14.  Assuming Grade â‰¥  2 CRS 
rate in the placebo arm is 50% (Nastoupil et al 2020 ) and a 20% in the treatment ar m (~30% 
change in CRS rate), a sample size of 23 evaluable participants per group would provide 70% 
power based on a 1-sided Ty pe-I error rate of 5%.  Sufficient number of participants will be 
enrolled to yield 23 evaluable participants in each group.  
A Bayesian interpretation for the selection and impact of the sample size can be provided in 
terms posterior probabilities.  As the  response rate based on CRS grade has a binomial (n, p) 
distribution with s number of responders out of n participants, it is common to use a conjugate 
Beta (a, b) prior which will lead to a Beta(a  + s, b + n âˆ’ s) posterior distribution.  For this 
exercise , we will assume a noninformative Beta(1,1) (~ Uniform(0,1) prior ). 
Table  19 presents scenarios of Bayesian posterior probability of demonstrating a treatment 
difference (â‰¥ 30%) by Day 14 in response rates , between the itacitinib 200  mg BID group and 
the placebo group , under various response rates (number and percentage of responders) . 
Incyte Corporation  Page 66 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Table  19: Bayesian Posterior Probability of Demonstrating a Treatment Difference  
Na (%) 200 BID Group  Nb (%) Placebo  Posterior Probabilityc 
2 (8.7)  9 (39.1)  43.7 
12 (52.5)  79.4 
14 (60.9)  93.4 
5 (21.7)  9 (39.1)  13.9 
12 (52.5)  45.9 
14 (60.9)  67.9 
7 (30.4)  9 (39.1)  4.7 
12 (52.5)  22.7 
14 (60.9)  44.7 
a Number of participants with CRS â‰¥ Grade 2, out of 23 participants, in the 200 mg BID group.  
b Number of participants with CRS â‰¥ Grade 2, out of 23 participants, in the p lacebo group.  
c Bayesian posterior probability that the itacitinib group has at least 30% improvement over placebo, base d on CRS 
â‰¥ Grade 2.  
Based on the scenarios presented in Table  19, if we assume observed CRS rates (CRS â‰¥  Grade 2) 
of 2/23 (8.7%) and 12/23 (52.2%) in the  itacitinib and placebo groups, respectively, then a 
Bayesian calculation is expected to yield a posterior probability of 79.4% of seeing an increase 
of at least 30% in the placebo group.  
10.2. Populations for Analysis  
Table  20 presents the populations for analysis.  
Table  20: Populations for Analysis  
Population  Description  
Safety population  The safety population includes all enrolled pa rticipants  who received at 
least 1 dose of study treatment . 
All safety analyses will be conducted using the safety po pulation.  
Efficacy evaluable 
analysis set (EAS)  The EAS includes all participants  who have received at least 1 dose of 
study treatment  and have received IEC therapy.  
All efficacy analyses will be conducted using EAS . 
 
  
 
 
 
 
 

Incyte Corporation  Page 67 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  10.3. Level of Significance  
Part 1:  There is no formal hypothesis testing in this study.  CRS rate as well as associated 95% 
exact CI by Clopper -Pearson method will be provided  (Clopper and Pearson 1934 ). 
Part 2 :  For the efficacy endpoints subjected to hypothesis testing, the 1 -sided Type I error will 
be controlled at 0.05 for each individual cohort expansion.  For other endpoints, CIs will be 
reported at a 95% confidence level.  
10.4. Statistical Analyses  
The Statistic al Analysis Plan will be developed and finalized before database lock and will 
describe the participant populations to be included in the analyses and procedures for accounting 
for missing, unused, and spurious data.  This section is a summary of the plann ed statistical 
analyses of the primary and secondary endpoints.  Analysis will be summarized by  IEC therapy  
and overall population in both efficacy and safety analysis.  
10.4.1.  Primary Analysis  
10.4.1.1.  CRS Rate by Day 14  
The primary endpoint of the study is CRS rate by D ay 14, defined as the percentage of 
participants experiencing â‰¥ Grade 2 CRS by Day 14 .  The primary analysis of CRS rate will be 
based on the EAS in overall population.  CRS rate and its exact 95%  CI will be presented.  In 
addition, CRS rate will be provid ed separately for each IEC therapy.  
10.4.1.2.  Cytokine Release Syndrome Rate by Day 14 â€“ Part 2  
The primary endpoint of the study is CRS rate by Day 14, defined as the percentage of 
participants experiencing â‰¥ Grade 2 CRS by Day 14.  The primary analysis of CRS rat e will be 
based on the EAS in overall population.  The primary hypothesis to be tested is to compare 
itacitinib 200 BID versus placebo.  CRS rates will be compared using a 1-sided (ï¡=0.05) test and 
will be complemented by a 95% CI.  
As sensitivity and suppo rtive analysis, Bayesian posterior probabilities  of crossing various 
thresholds of improvements over placebo (eg, 30%), as well as credible intervals will be 
compu ted using a noninformative Uniform (0 ,1) prior . 
10.4.2.  Secondary Analysis  
10.4.2.1.  Part 2  Analysis  
The secondary analysis in Part 2 will be conducted by first comparing the itacitinib 200  mg QD 
dose from Part 1 with the placebo group in Part 2, using a 95% CI.  This comparison will include 
participants who were treated with Yescarta, thus ensuring simil arity in the underlying 
population.  A sensitivity analysis will also be conducted as an empirical compar ison between 
treatment groups.  
Comparisons between treatment groups will be done at the summary level, based on rates and 
CIs, which will add to the de termination of the optimal dose and schedule of itacitinib for 
subsequent trials.  Pairwise Cochran -Mantel -Haenszel  tests and trend tests (eg, 
Incyte Corporation  Page 68 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL   
  Final dose sel ection will include results from these tests as well as from other 
endpoints including safety, rescue medication required  
Similar comparisons between the treatment  groups and placebo will also be conducted for other 
secondary endpoints  explored in Part 1 , as explained  in section s below .  Evidence from these 
comparisons will also be used in selecting the optimal dose and schedule of itacitinib for 
subsequent trials.  
10.4.2.2.  ICANS Incidence  
Incidence of ICANS, defined as the percentage of partici pants experiencing ICANS over 28 -day 
period, will be presented together with its exact 95% CI.  In addition, the most severe ICANS 
within each participant will be summarized by frequency count.  There is no missing data 
imputation in calculation of ICE sco re or ICANS grading.  In addition, ICANS incidence will be 
provided separat ely for each IEC therapy . 
10.4.2.3.  Onset and Duration of ICANS  
Time to first onset of ICANS from date of IEC infusion will be sum marized within the first 
28 days.  Participants without ICANS  will be considered as missing and not included in the 
summary.  Duration of multiple occurrence of ICANS within each participant will be added 
together regardless of grading.  Summary statistics including mean, median, standard  deviation, 
minimum , and max imum will be provided for time to first onset o f ICANS and duration of 
ICANS.  
10.4.2.4.  Onset and Duration of CRS  
Time to first onset of CRS from date of IEC infusion will be summarized wi thin the first 
28 days.  Participants without CRS will be considered as missin g in the summary statistics.  
Duration of multiple occurrence of CRS within each participant will be added together regardless 
of grading.  Summary statistics including mean, median, standard  deviation, minimum , and 
maximum will be provided for time to fir st ons et of CRS and duration of CRS.  
10.4.2.5.  Occurrence  of CRS Within 48 Hours  
Percentage of participants who developed CRS within 48 hours of IEC infusion will be 
summarized.  Two-sided 95% exact CI will be provided.  
10.4.2.6.  CRS Rate Within 28 Days  
Percentage of participants who developed CRS within 28 days  of IEC infusion will be 
summarized.  Two-sided 95% exact CI will be provided.  
10.4.2.7.  Hospitalization on Study  
Number of hospitalization associated with total duration of hospitalization  will be summariz ed.  
Cause of hospitalization will be provided as well.  

Incyte Corporation  Page 69 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  10.4.3.  Safety Analyses  
Safety analyses will be conducted for the safety population.  All safety will be summarized by  
IEC therapy  and overall population.  Specific safety may also be summarized by underlying  
disease as needed.  
Safety summaries will also be presented by the 2 dose groups and placebo for all the safety 
endpoints that are described below .  This additional information will be used to confirm the 
optimal dose selection.  
10.4.3.1.  Adverse Events  
Adverse even ts will be coded by the Medical Dictionary for Regulatory Activities  dictionary, 
and TEAEs (ie, AEs reported for the first time or worsening of a pre -existing event after first 
dose of study treatment ) will be tabulated by preferred term and system organ c lass for all 
events, related events, and events of Grade 3 or higher.  
10.4.3.2.  Clinical Laboratory Tests  
The clinical laboratory data will be analyzed using summary statistics.  In addition, distributions 
of key laboratory parameters may be plotted over time; these  values will also be classified into 
CTCAE toxicity grades and tabulated.  
Laboratory test values outside the normal range will be assessed for severity based on the normal 
ranges for the clinical reference laboratory.  The incidence of abnormal laboratory values and 
shift tables relative to baseline will be tabulated.  The following summaries will be produced for 
the laboratory data:  
â€¢ Number and percentage of participants with worst post baseline  CTCAE grade 
(regardless of baseline value).  Each participant will be counted only for the worst 
grade observed postbaseline . 
â€¢ Shift tables from baseline to the worst post baseline  value using CTCAE grade.  
â€¢ For laboratory parameters where CTCAE grades are not defined, shift tables to the 
worst post baseline  value using  the low/normal/high classifications based on 
laboratory reference ranges.  
10.4.3.3.  Vital Signs  
Descriptive statistics and mean change from baseline will be determined for vital signs (blood 
pressure, pulse, respiratory rate, and body temperature) at each assessmen t time.  Vital sign 
results will be reviewed for clinically notable abnormalities, and participants exhibiting clinically 
notable vital sign abnormalities will be listed.  
Incyte Corporation  Page 70 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  10.4.3.4.  Dose Intensity  
Measures of exposure (eg, days of exposure, drug compliance, dose inte nsity) of study drug will 
be summarized by means of summary statistics.  
10.5. Interim Analysis  
For Part 1, a n interim analysis is planned after approximately 24 participants are dosed with IEC 
therapy and complete  the Day 28 ( EOT) visit.  The results from the interim analysis will be 
reviewed by the DSMB .  The primary intent of this analysis is to minimize unnecessary exposure 
to itacitinib  in the event of futility of preventing CRS.  The study may be stopped for futility at 
the interim analysis if the conditional power based on interim results is lower than  20%, which is 

Incyte Corporation  Page 71 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  equivalent to more than 17 out of 24 participants experiencing â‰¥  Grade 2 CRS by Day 14.  More 
than 24 participants  may be available in EAS at the time of interim analysis , and t he stopping 
boundary will be re -evaluated at the time of the ana lysis.    
  Enrollment will continue 
while the analysis is being conducted, and the study Statistical Analysis Plan will describe the 
planned interim analysis in greater detail.  
No interim analysis is planned for Part 2.  

Incyte Corporation  Page 72 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Responsibilities  
â€¢ The Protocol, Protocol Amendments, ICF, IB, and other relevant documents 
(eg, advertisements) must be submitted  to an IRB/IEC by the investigator and 
reviewed and approved by the IRB/IEC and health authorities before the study is 
initiated.  
â€¢ The investigator is responsible for ensuring that the safety reports provided by the 
sponsor are reviewed and processed in acc ordance with regulatory requirements, the 
policies and procedures established by the IRB/IEC, and institutional requirements.  
â€¢ Any amendments to the Protocol will require approval from both health authorities 
and the IRB/IEC before implementation of changes  made to the study design, except 
for changes necessary to eliminate an immediate hazard to study participants.  
â€¢ The investigator will be responsible for the following:  
âˆ’ Providing written summaries of the status of the study to the IRB/IEC annually or 
more f requently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC.  
âˆ’ Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures.  
âˆ’ Providing oversight of the conduct of the study at the  site and adherence to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country -specific regulations.  
â€¢ Adhering to the Protocol as described in this document and agreeing that changes to 
the Protocol procedures, with the except ion of medical emergencies, must be 
discussed and approved, first, by the sponsor or its designee and, second, by the 
IRB/IEC. Each investigator is responsible for enrolling participants who have met the 
specified eligibility criteria.  
â€¢ Retaining records in  accordance with all local, national, and regulatory laws but for a 
minimum period of at least 2  years after the last marketing application approval in an 
ICH region and until there are no pending or contemplated marketing applications in 
an ICH region, or  if not approved, 2  years after the termination of the test article for 
investigation to ensure the availability of study documentation should it become 
necessary for the sponsor or a regulatory authority to review.  
âˆ’ The investigator must not destroy any re cords associated with the study during the 
retention period without receiving approval from the sponsor. The investigator 
must notify the sponsor or its designee in the event of accidental loss or 
destruction of any study records. If the investigator leave s the institution where 
the study was conducted, the sponsor or its designee must be contacted to arrange 
alternative record storage options.  
Incyte Corporation  Page 73 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  âˆ’ All eCRF data entered by the site (including audit trail), as well as computer 
hardware and software (for accessin g the data), will be maintained or made 
available at the site in compliance with applicable record retention regulations. 
The sponsor will retain the original eCRF data and audit trail.  
11.2. Data Management  
Data management will be performed in a validated EDC s ystem.  The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion guidelines for instructions on data entry in the 
eCRF.  The study monitor will reference the Monitoring Plan in order to ensure that each issue 
identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan 's requirements.   Other data outside the EDC system required in the study conduct 
of the Protocol , such as documents or results transmitted to the sponsor via a central laboratory 
or specialized technical vendors, and as designated by the sponsor, will have their own data flow 
management plans, or study charters, or  plans, as applicable.  
The sponsor (or designee) will be responsible for the following:  
â€¢ Managing the integrity of the data and the quality of the conduct of the study, such as 
ensuring that study monitors perform ongoing source data verification to confirm that 
data entered into the eCRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved  Protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
â€¢ Managing and reconciling the data generated and/or collected, including documents 
and results such as laboratory or imaging data analyzed centrally by a designat ed 
vendor of the sponsor.  
The investigator will be responsible for the following:  
â€¢ Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
â€¢ Delivering, or ensuring the delivery of, all other results, documents, data, kno w-how, 
or formulas relating to the study to the sponsor or designee electronically and/or 
centrally (eg, laboratory data, imaging data,  photographs, diary data) 
or as otherwise specified in the Protocol.  
â€¢ Maintaining adequate and accurate so urce documents and trial records that include all 
pertinent observations on each of the site's trial participants. Source data should be 
attributable, legible, contemporaneous, original, accurate, and complete. Changes to 
source data should be traceable, s hould not obscure the original entry, and should be 
explained if necessary (eg, via an audit trail). Source data are, in general, all 
information in original records and certified copies of original records of clinical 
findings, observations, or other acti vities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data are contained in source 
documents (original records or certified copies).  

Incyte Corporation  Page 74 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  â€¢ Verifying that data entries are accurate and correct by physically or electronica lly 
signing the eCRF.  
â€¢ Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF, sent to a central vendor designated by the sponsor, or as 
described in other study and data flow manuals.  
âˆ’ Source documents provide evi dence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed and 
available at the investigator's site. Examples of source documents are original 
documents, data, and records (eg, hospital recor ds; electronic hospital records; 
clinical and office charts; laboratory notes; memoranda; participants' diaries or 
evaluation checklists; pharmacy dispensing records; recorded data from 
automated instruments; copies or transcriptions certified after verifi cation as 
being accurate copies; microfiches; photographic negatives; microfilm or 
magnetic media; x -rays; participants' files; and e -records/records kept at the 
pharmacy, at the laboratories, and at medico -technical departments involved in 
the clinical tr ial). 
âˆ’ Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, 
depending on t he study. Current applicable medical records must be available.  
â€¢ Sending participants' data, either as unique samples, copies, or photographs, to be 
evaluated centrally or analyzed centrally, or both, by a qualified vendor designated by 
the sponsor.  
âˆ’ As requ ired by privacy and data protection regulations and Incyte's privacy 
policies, if any photographs of participants are to be taken, the photographs must 
be limited to the area of the face or the body that is strictly necessary and the 
photographs should be masked (ie, identifying features such as eyes, mouth, scars, 
tattoos, or unique markings or features should be either obscured with a black bar 
or digitally pixelated so as to not permit the reidentification of the participants and 
preserve their confident iality) by a specially designated photography vendor prior 
to sending the photographs to Incyte or any other third -party vendors for analysis 
or further processing.  
â€¢ Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspect ions by providing direct access to source data and other relevant clinical study 
documents.  
âˆ’ Monitoring: Qualified representatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan. The 
investigator mus t allow the study monitors to review any study materials and 
participant records at each monitoring visit.  
Incyte Corporation  Page 75 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  âˆ’ Auditing: Qualified representatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the P rotocol, 
applicable local clinical study regulations, and overall study conduct. The 
investigator must allow the auditors to review original source records and study 
documentation for all participants.  
âˆ’ Regulatory inspection: Regulatory authorities may cond uct an inspection of the 
study and the site at any time during the development of an investigational 
product. The investigator and staff are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other 
study-related documents. The investigator must immediately notify the sponsor 
when contacted by any regulatory authority for the purposes of conducting an 
inspection.  
11.3. Data Quality Assurance  
The sponsor assumes accountability for actions delegated to other i ndividuals (eg, contract 
research organizations).  The sponsor or designee is responsible for the data management of this 
study, including quality checking of the data.  Further, monitoring details describing strategy, 
including definition of study -critica l data items and processes (eg, risk -based initiatives in 
operations and quality such as risk management and mitigation strategies and analytical 
risk-based monitoring), methods, responsibilities, and requirements, including handling of 
noncompliance issue s, Protocol deviations, and monitoring techniques (eg, central, remote, or 
on-site monitoring) are provided in the monitoring plan.  
Quality tolerance limits will be predefined in the operational manual to identify systematic issues 
that can impact particip ants' safety, efficacy results and analysis, and/or reliability of study 
results.  These predefined parameters will be monitored during the study and can be adjusted 
during the study upon data review.  Important deviations from the quality tolerance limits  and 
remedial actions taken, including reporting to IRBs/IECs and health authorities if applicable, will 
be summarized in the CSR.  
11.4. Data Privacy and Confidentiality  of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data protection laws 
and regulations.  The investigator and the sponsor or its designee are responsible for ensuring 
that personal information is handled in accordance with local data protection laws (including , but 
not limited to Health Insurance Portabil ity and Accountability Act of 1996 and General Data 
Protection Regulation ) as applicable, and the sponsor operates comprehensive data privacy and 
data security programs that are applicable to this study.  Appropriate notice, or notice and 
consent (as may b e required by each applicable jurisdiction), for collection, use, disclosure, 
and/or transfer (if applicable) of personal information must be obtained in accordance with local 
data protection laws.  Appropriate data protection terms that comply with applic able laws will be 
included in relevant study agreements.  
To ensure confidentiality of records and protect personal data, participant names will not be 
supplied to the sponsor or its designee.  Only the participant number will be recorded in the 
eCRF; if th e participant's name appears on any other document (eg,  laboratory report), it must be 
obliterated on the copy of the document to be supplied to the sponsor or its designee.  Study 
Incyte Corporation  Page 76 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  findings stored on a computer will be stored in accordance with appropriate  technical and 
organizational measures as required by local data protection laws.  
In the event of a data breach involving participant data, the sponsor or its designee will follow 
the sponsor's incident response procedures.  The precise definition of a dat a breach varies in 
accordance with applicable law but may generally be understood as a breach of security leading 
to the accidental or unlawful destruction, loss, alteration, unauthorized disclosure of, or access to, 
personal data.  In accordance with its incident response procedures, the sponsor will assess the 
breach to consider its notification and remediation obligations under applicable law.  
11.5. Financial Disclosure  
Before study initiation, all clinical investigators participating in clinical studies subje ct to FDA 
Regulation Title 21 CFR Part 54 â€“ Financial Disclosure by Clinical Investigators (ie, "covered 
studies ") are required to submit a completed Clinical Investigator Financial Disclosure form that 
sufficiently details any financial interests and arra ngements that apply .  For the purpose of this 
regulation, "clinical investigator " is defined as any investigator or subinvestigator who is directly 
involved in the treatment or evaluation of research participants, including the spouse and each 
dependent ch ild of the clinical investigator or subinvestigator .  These requirements apply to both 
US and foreign clinical investigators conducting covered clinical studies.  
Any new clinical investigators added to the covered clinical study during its conduct must als o 
submit a completed Investigator Financial Disclosure Form .  During a covered clinical study, 
any changes to the financial information previously reported by a clinical investigator must be 
reported to the sponsor or its designee .  At the conclusion of the covered clinical study, the 
clinical investigators will be reminded of their obligations .  In the event that the clinical 
investigator is not reminded, they nevertheless will remain obligated to report to the sponsor or 
its designee any changes to the financial information previously reported, as well as any changes 
in their financial information for a period of 1 year after completion of the covered clinical study.  
11.6. Publication Policy  
By signing the study Protocol, the investigator and their institution  agree that the results of the 
study may be used by the sponsor, Incyte Corporation (Incyte), for the purposes of national and 
international registration, publication, and information for medical and pharmaceutical 
professionals. Study results will be publ ished in accordance with applicable local and national 
regulations. If necessary, the authorities will be notified of the investigator's name, address, 
qualifications, and extent of involvement. The terms regarding the publication of study results 
are cont ained in the agreement signed with the sponsor or its designee. A signed agreement will 
be retained by the sponsor or its designee.  
The results of this study may be published or presented at scientific meetings .  If this is foreseen, 
the investigator agree s to submit all manuscripts or abstracts to the sponsor before submission .  
This allows the sponsor to protect proprietary information and to provide comments . 
The sponsor will comply with the requirements for publication of study results .  In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data .  In this case, a 
coordinating investigator will be designated by mutual agreement.  
Incyte Corporation  Page 77 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Authorship will be determined in line with International Committee of Medical Journal Editors 
authorship requirements.  
11.7. Study and Site Closure  
The sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at  the sole discretion of the sponsor .  Study sites will be closed upon study 
completion .  A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The investigato r may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not li mited to:  
â€¢ Failure of the investigator to comply with the protocol,  the requirements of the IRB  or 
local health authorities, the sponsor 's procedures, or GCP guidelines . 
â€¢ Inadequate recruitment of participants by the investigator . 
â€¢ Discontinuation of further study treatment  development . 
Incyte Corporation  Page 78 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  12. REFERENCES  
Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic 
leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event 
in a phase I clinical trial. Mol  Ther 2010;18:666 -668. 
Brudno JN, Kochenderfer JN. Toxicities of chim eric antigen receptor T cells: recognition and 
management. Blood 2016 ,127;3321 -3330 . 
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and 
response assessment of Hodgkin and non -Hodgkin lymphoma: the Lugano classification. J Clin 
Oncol 2014;32:3059 -3068.  
Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy 
testing in clinical trials. 2014. http://www.hma.e u/ctfg.html. Accessed July 12, 2019.  
Clopper C , Pearson ES . The use of confidence or fiducial limits illustrated in the case of the 
binomial. Biometrika 1934; 26:404 -413. 
European Medicines Agency. Guideline on the Investigation of Drug Interactions. 2012.  
Food and Drug Administration. Guidance for Industry: In Vitro Metabolism - and Transporter -
Mediated Drug -Drug Interaction Studies. 2017.  
Guschin D, Rogers N , Briscoe J, et al. A major role for the protein tyrosine kinase JAK1 in the 
JAK/STAT signal transduc tion pathway in response to interleukin -6. EMBO J 
1995;14 :1421 -1429.  
 
 
Itaciti nib Investigator 's Brochure. Wilmington, DE: Incyte Corporation.  
Kotch C, Barrett D, Teache y DT . Tocilizumab for the treatment of c himeric antigen receptor T 
cell-induced cytokine release syndrome. Expert Rev Clin Immunol 2019.  
Kymriah (tisagenlecleucel) [ prescribing information]. Novartis Pharmaceuticals Corporation; 
May 2018.  
Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric 
antigen receptor T  cell-induced severe or life-threatening cytokine release syndrome. Oncologist 
2018 ;23:943-947. 
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of 
cytokine release syndrome. Blood 2014 ;124:188-195. 
Lee DW, Santomasso BD, Locke FL , et al. ASBMT Consensus Grading for Cytokine Release 
Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow 
Transplant 2018;18:31691 -3164. 
Murray PJ. The JAK -STAT signaling pathway: input and output integration. J Immunol 
2007 ;178:2623 -2629.  

Incyte Corporation  Page 79 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Nastoupil LJ, Jain MD, Feng L, et a l. Standard -of-care axicabtagene ciloleucel for relapsed or 
refractory large B -cell lymphoma: results from the US Lymphoma CAR T consortium. J Clin 
Oncol 2020;38:3119 -3128.  
Neelapu SS . Managing the toxicities of CAR T -cell therapy. Hematol Oncol 
2019;37(S uppl 1):48 -52. 
Neelapu SS, Locke FL, Bartlett, et al. Axicabtagene ciloleucel CAR T -cell therapy in refractory 
large B -cell lymphoma. N Engl J Med 2017;377:2531 -2544.  
Neelapu SS, Tummala S, Kebriaei P, et al.  Chimeric antigen receptor T -cell therapy - asses sment 
and management of toxicities.  Nat Rev Clin Oncol  2018 ;15:47 -62. 
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol 1982;5:649 -655. 
Park JH, RiviÃ¨re I, Gonen M, et al. Long -term follow -up of CD19 CAR therapy in acute 
lymphoblastic leukemia. N Engl J Med 2018;378:449 -459. 
PRECLIN -19.16.1. Summary Report: Itacitinib (INCB039110) for the prevention of cytokine 
release syndrome (CRS) induced by Chimeric Antigen Receptor T -cells (C AR-T-cells) therapy. 
Wilmington, DE: Incyte Corporation. Approval Date:  15 JUL 2019 . 
 
 
 
Tecartus (brexucabtagene autoleucel) [prescribing i nformation]. Kite Pharma, Inc.; 2020.  
Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen 
receptor engineered T cells. Ca ncer Lett 2014;343:172 -178. 
Yescarta (axicabtagene ciloleucel) [prescribing i nformation]. Kite Pharma, Inc.; 2021 . 
 
 
 

Incyte Corporation  Page 80 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S 
For male participants in the study:  
Male participants should use a condom from screening through 90 days after the end of systemic 
exposure.  If the male participant has a partner that is of child -bearing potential, the partner should also 
use contraception through 90 days after the end of relevant systemic exposure.  In addition, male 
participants must refra in from donating sperm from screening through 90 days after the end of relevant 
systemic exposure.  Males who have had a vasectomy qualify as having met the requirement for a 
highly effective birth control method.  
For female participants in the study:  
The following methods that can achieve a failure rate of less than 1% per year when used consistently 
and correctly are considered as highly effective birth control methods:  
â€¢ Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulationa 
âˆ’ oral 
âˆ’ intravaginal  
âˆ’ transdermal  
â€¢ Progestogen -only hormonal contraception associated with inhibition of ovulationa 
âˆ’ oral 
âˆ’ inject able 
âˆ’ implantableb 
â€¢ Intrauterine deviceb 
â€¢ Intrauterine hormone -releasing systemb 
â€¢ Bilateral tubal occlusionb 
â€¢ Vasectomized partnerbc 
â€¢ Sexual abstinenced 
Acceptable birth control methods that result in a failure rate of more than 1% per year include:  
â€¢ Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary 
mode of action  
â€¢ Male or female condom with or without spermicidee 
â€¢ Cap, diaphragm, or sponge with spermicidee 
â€¢ Tubal ligation  
a Hormonal contraception may be su sceptible to interaction with the investigational medicinal product, which may 
reduce the efficacy of the contraception method.  
b Contraception methods that in the context of this guidance are co nsidered to have low user dependency.  
c Vasectomized partner is a highly effective method of avoiding pregnancy provided that partner is the sole sexual 
partner of the woman of childbearing potential study participant and that the vasectomized partner has received 
medical assessment of the surgical success.  
d In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical stud y and the 
preferred and usual lifestyle of the participant.  
e A combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) 
are also considered accep table, but not highly effective, birth control methods.  
Source:  Clinical Trial Facilitation Group 2014 . 
Incyte Corporation  Page 81 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  APPENDIX  B. CYTOCHROME P450 AND P-GLYCOPROTEIN 
INHIBITORS AND CYTOC HROME P450 INDUCERS  
The Food and Drug Administration (FDA) Drug Development and Drug Interactions:  Table of 
Substrates, Inhibitors and Inducers.   
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteracti
onsLabeling/ucm093664.htm#table3 -3.  Accessed July 9, 2019.  
Incyte Corporation  Page 82 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  APPENDIX  C. INSTRUCTION TO PART ICIPANTS FOR HANDLING 
STUDY TREATMENT  
The participant must be instructed in the handling of study treatment  as follows:  
â€¢ Store the study treatment  at room temperature , in a safe place, and out of the reach of 
children.  
â€¢ Only remove the number of tablets needed at the time of administration.  
â€¢ Not to remove tablets  in advance of the next scheduled administration.  
â€¢ Make every effort to take doses on schedule.  
â€¢ Report any missed tablets  and/or doses . 
â€¢ To take study treatment  with a full glass of  water.  
â€¢ If the participant vomits after taking study treatment , the participant should not take 
another dose.  
â€¢ To keep study treatment  in a safe place and out of reach of children.  
â€¢ To bring all used and unused study treatment  bottles/kits to the site at eac h visit.  
â€¢ To refrain from taking study medication on the day of clinic visits until after blood 
samples are collected.  
 . 
â€¢ If an study treatment  dose is missed by more than 8 hours, that dose should be 
skipped and the next scheduled dose should be  administered at the usual time . 

Incyte Corporation  Page 83 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  APPENDIX  D. MANAGEMENT OF POTENTI AL HY 'S LAW CASES  
INTRODUCTION  
During the course of the study , the investigator will remain vigilant for increases in liver 
biochemistry.  The investigator is responsible for det ermining whether a participant  meets 
potential Hy 's law (PHL) criteria at any point during the study.  
The investigator participates, in conjunction with Incyte clinical project and pharmacovigilance 
representatives, in the review and assessment of cases fu lfilling PHL criteria to ascertain whether 
there is an alternative explanation for the elevations in liver biochemistry other than 
drug-induced liver injury caused by the study treatment . 
The investigator fulfil ls requirements for the recording of data per taining to PHL or Hy 's law 
cases and AE/SAE reporting according to the outcome of the review and assessment in line with 
standard safety reporting processes.  
DEFINITIONS  
For the purpose of this process definitions are as follows  
Potential Hy 's Law  
An increase in AST or  ALT > 3 Ã— ULN and total bilirubin > 2 Ã— ULN at any point during the 
study.  The elevations do not have to be at the same time or within a specified timeframe.  
Hy's Law  
An increase in AST or ALT > 3 Ã— ULN and total bilirubin > 2 Ã— ULN, where no other reason can 
be found to explain the combination of increases, eg, elevated serum ALP indicating cholestasis, 
viral hepatitis, another drug.  
ACTIONS REQUIRED IN CASES OF AST OR ALT  > 3 Ã— ULN OR TOTAL BILIRUBIN 
â‰¥ 2 Ã— ULN  
Identification and Dete rmination of Potential Hy 's Law  
To identify cases of AST or ALT > 3 Ã— ULN or total bilirubin > 2  Ã— ULN and consequently 
determine whether the participant  meets PHL criteria, please follow the instructions below:  
â€¢ Review the laboratory report and if a partic ipant  has AST or ALT > 3 Ã— ULN OR 
total bilirubin > 2 Ã— ULN at any visit:  
âˆ’ Determine without delay whether the participant  meets PHL criteria by reviewing 
laboratory reports from all previous visits.  
âˆ’ Enter the laboratory data into the laboratory eCRF as soo n as possible.  
Incyte Corporation  Page 84 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Potential Hy 's Law Criteria Not Met  
If the participant  has NOT had AST or ALT > 3 Ã— ULN AND total bilirubin > 2 Ã— ULN at any 
point in the study (the elevations do not have to be at the same time or within a specified 
timeframe), irrespective  of ALP, please follow the instruction below:  
â€¢ Perform follow -up on subsequent laboratory results according to the guidance 
provided in Section  6.1.3  of the Protocol.  
Potential Hy 's Law Criteria Met  
If the participant  has had AST or ALT > 3 Ã— ULN AND total bilirubin > 2 Ã— ULN at any point in 
the study (the elevations do not have to be at the same time or within a specified timeframe), 
irrespective of A LP, please follow the instruction below:  
â€¢ Have participant  discontinue  study treatment . 
â€¢ Notify Incyte study team without delay.  
âˆ’ The investigator, or designee, should contact the medical monitor to discuss and 
agree upon an approach for the study participant 's follow -up and the continuous 
review of data.  
â€¢ Monitor the participant  until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as medically indicated.  
â€¢ Investigate the etiology of the event an d perform any relevant diagnostic 
investigations as discussed with the medical monitor.  
â€¢ Enter the laboratory data into the laboratory CRF as soon as possible.  
â€¢ If at any time (in consultation with the medical monitor) the PHL case meets serious 
criteria, re port it as an SAE using standard reporting procedures.  
REVIEW AND ASSESSMENT  
No later than 3 weeks after the biochemistry abnormality was initially detected and the criteria 
for PHL was met, the medical monitor, Incyte pharmacovigilance physician, and investigator 
will discuss and review available data and agree on whether there is  an alternative explanation 
for the elevations in liver biochemistry other than drug -induced liver injury caused by the study 
treatment .  Participant  matter experts will be included in the review as appropriate.  
Evaluation of Alternative Causes  
In order to  gather additional clinical information to seek other possible causes of the observed 
liver test abnormalities, the following alternative etiologies should be considered, including, but 
not limited to,  
â€¢ Active viral hepatitis  
â€¢ Alcoholic and autoimmune hepati tis 
Incyte Corporation  Page 85 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  â€¢ Hepatobiliary disorders  
âˆ’ Biliary tract disease, such as migration of gallstones or intrahepatic lesions, more 
often causes cholestatic injury initially and should be investigated with gall 
bladder and ductal imaging studies, especially if alkaline phosp hatase is 
increased.  Malignant interruption of the biliary tract also should be considered.  
â€¢ Concomitant treatment  
â€¢ Other causes such as systemic infections (bacterial, fungal, viral), nonalcoholic 
steatohepatitis, and cardiovascular diseases  
Actions After Review and Assessment  
According to outcome of the review and assessment, please follow the instructions below:  
If there is an agreed alternative explanation for the AST or ALT and total bilirubin elevations, a 
determination of whether the alternative expla nation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE.  
â€¢ If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF if possible.  
â€¢ If the alternative explanation is an AE/SAE, reco rd the AE/SAE in the eCRF 
accordingly and follow the standard study processes.  
â€¢ Have participant  resume study treatment  as per Protocol guidelines.  
If it is agreed that there is no explanation that would explain the AST or ALT and total bilirubin 
elevations : 
â€¢ Have participant  permanently discontinue study treatment  and perform end-of-
treatment procedures.  
â€¢ Report an SAE (report term "Hy's Law "). 
âˆ’ The 'medically important ' serious criterion should be used if no other serious 
criteria apply.  
âˆ’ As there is no altern ative explanation for the Hy 's law case, a causality assessment 
of related should be assigned.  
â€¢ If there is an unavoidable delay of over 3 weeks in obtaining the information 
necessary to assess whether or not the case meets the criteria for a Hy 's law case,  then 
it is assumed that there is no alternative explanation until such time as an informed 
decision can be made.  Report an SAE (report term "Potential Hy 's Law ") applying 
serious criteria and causality assessment as per above.  
Incyte Corporation  Page 86 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  ACTIONS REQUIRED FOR REPEAT  EPISODES OF AST OR ALT > 3 Ã— ULN AND/OR 
TOTAL BILIRUBIN > 2 Ã— ULN  
The requirement to conduct follow -up, review, and assessment of a repeat occurrence(s) of PHL 
is based on the nature of the alternative cause identified for the previous occurrence.  
If the alternative cause for the previous occurrence of PHL was not chronic or progressing 
malignant disease, please follow the process for PHL review and assessment as described in this 
appendix.  
If the alternative cause for the previous occurrence of PHL was ch ronic or progressing malignant 
disease , please follow the instructions below:  
â€¢ Determine  whether there has been a significant change* in the participant 's condition.  
âˆ’ If there is no significant change, no action is required.  
âˆ’ If there is a significant change,  follow the process described for PHL review and 
assessment as described in this appendix.  
* A 'significant ' change in the participant 's condition refers to a clinically relevant change in ALT, AST, or total 
bilirubin, or associated symptoms.  The determin ation of whether there has been a significant change will be at the 
discretion of the investigator; this may be in consultation with the medical monitor if there is any uncertainty.  
Incyte Corporation  Page 87 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  APPENDIX  E. RESPONSE CRITERIA FOR  LYMPHOMA  â€“ THE 
LUGANO CLASSIFICATIO N 
Site PET â€“Based Response  CT/MRI -Based Response  
 Complete metabolic response  Complete radiologic response  
(all of the following)  
Lymph nodes and 
extralymphatic 
sites Score 1, 2, or 3 with or without a residual 
mass on 5PS.a Target nodes/nodal masses must regress to 
â‰¤ 1.5 cm in LDi.  
Nonmeasured 
lesion  Not applicable.  Absent.  
Organ enlargement  Not applicable.  Regress to normal.  
New lesions  None.  None.  
Bone marrow  No evidence of FDG -avid disease in 
marrow.  Normal by morphology; if indeterminate, IHC 
negative.  
 Partial metabolic response  Partial remission (all of the following)  
Lymph nodes and 
extralymphatic 
sites â€¢ Score 4 or 5a with reduced uptake 
compared with baseline and residual 
mass( es) of any size.  â€¢ â‰¥ 50% decrease in SPD of up to 6 target 
measurable nodes and extranodal sites.  
â€¢ When a lesion is too small to measure on 
CT, assign 5 mm Ã— 5 mm as the default 
value.  
â€¢ When no long er visible, 0 Ã— 0 mm.  
For a node > 5 mm Ã— 5 mm but smaller than 
normal, use actual measurement for 
calculation.  
Nonmeasured 
lesions  Not applicable.  Absent/regressed, but no increase.  
Organ enlargement  Not applicable.  Spleen must have regressed by > 50% in 
length beyond normal.  
New lesions  None.  None.  
Bone marrow  Residual uptake higher than uptake in 
normal marrow but reduced compared 
with baseline (diffuse uptake compatible 
with reactive changes from chemotherapy 
allowed).  If there are persistent foca l 
changes in the marrow in the context of a 
nodal response, consideration should be 
given for further evaluation with MRI or 
biopsy at interval scan.  Not applicable.  
 No metabolic response  Stable disease  
Target nodes/  
nodal masses, 
extranodal lesions  Score of 4 or 5a with no significant 
change in FDG uptake from baseline at 
interim or EOT.  < 50% decrease from baseline in SPD of up to 
6 dominant, measurable nodes and extranodal 
sites; no crite ria for progressive disease are 
met. 
Nonmeasured 
lesions  Not applicable.  No increase consistent with progression.  
Organ enlargement  Not applicable.  No increase consistent with progression.  
New lesions  None.  None.  
Bone marrow  No change from baseline.  Not applicable.  
Incyte Corporation  Page 88 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Site PET -CTâ€“Based Response  CT-Based Response  
 Progressive metabolic disease:  Progressive disease (requires at least 1 of 
the following):  
Individual target 
nodes/nodal lesions  Individual target nodes/nodal lesions:  
â€¢ Score 4 or 5a with an increase in 
intensity of uptake from baseline and/or  
â€¢ New FDG -avid foci consistent with 
lymphoma at interim or EOT 
assessment.  
 
Extranodal lesions:  
â€¢ New FDG -avid foci consistent with 
lymp homa at interim or end -of-
treatment assessment.  
 
New lesions:  
â€¢ New FDG -avid foci consistent with 
lymphoma rather than another etiology 
(eg, infection, inflammation).  If 
uncertain regarding etiology of new 
lesions, biopsy or interval scan may be 
considered.  
 
Bone marrow:  
â€¢ New or recurrent FDG -avid foci.  PPD progression:  
â€¢ An individual node/lesion must be abnormal 
with all of the following:   
o LDi > 1.5 cm  
o Increase by â‰¥ 50% from PPD nadir  
o An increase in LDi or SDi from nadir  
â–ª 0.5 cm for lesions â‰¤ 2 cm  
â–ª 1.0 cm for  lesions > 2 cm  
â€¢ In the setting of splenomegaly, the splenic 
length must increase by >  50% of the extent 
of its prior increase beyond baseline (eg, a 
15 cm spleen must increase to > 16 cm).  If 
no prior splenomegaly, must increase by at 
least 2 cm from base line. 
â€¢ New or recurrent splenomegaly.  
â€¢ New or clear progression of pre -existing 
nonmeasured lesions.  
â€¢ Regrowth of any previously resolved 
lesions.  
â€¢ A new node > 1.5 cm in any axis.  
â€¢ A new extranodal site > 1.0 cm in any axis; 
if < 1.0 cm in any axis, its presence must be 
unequivocal and must be attributable to 
lymphoma.  
â€¢ Assessable disease of any size 
unequivocally attributable to lymphoma.  
â€¢ New or recurrent involvement of the bone 
marrow.  
Incyte Corporation  Page 89 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  APPENDIX  F. RESPONSE CRITERIA FOR  ACUTE LYMPHOBLASTIC  
LEUKEMIA  
Response Criteria  for Blood and Bone Marrow  
Complete response (CR)  â€¢ No circulating blasts or extramedullary disease.  
â€¢ No lymphadenopathy, splenomegaly, skin/gum 
infiltration/testicular mass/  central nervous system ( CNS ) 
involvement.  
â€¢ Trillneage hematopoiesis (TLH) and < 5% blasts.  
â€¢ Absolute neutrophil count (ANC) >  1.0 Ã— 109/L. 
â€¢ Platelets > 100  Ã— 109/L. 
â€¢ No recurrence for 4 weeks.  
Complete response with incomplete 
blood count recovery (CRi)  â€¢ Meets all criteria for CR except platelet count and/or ANC . 
Overall response rate (ORR)  â€¢ ORR = CR + CRi . 
Refractory disease  â€¢ Failure to achieve CR at the end of the induction . 
Progressive disease (PD)  â€¢ Increase of â‰¥ 25% in the absolute number of circulating or 
bone marrow blasts or development of extr amedullary disease.  
Relapsed disease  â€¢ Reappearance of blasts in the blood or bone marrow (>  5%) 
or in any extramedullary site after a CR . 
Response Criteria for CNS Disease  
CNS remission  â€¢ Achievement of CNS -1 status in a participant  with CNS -2 or 
CNS -3 status at diagnosis . 
CNS relapse  â€¢ New development of CNS -3 status or clinical signs of CNS 
leukemia such as facial nerve palsy, brain/eye involvement, 
or hypothalamic syndrome without another explanation.  
Response Criteria for Lymphomatous Extramedullary Disease  
Computed tomography (C T) of ne ck/chest/abdomen/pelvis with intravenous ( IV) contrast and positron 
emission tomography ( PET)/CT should be performed to assess response for extramedullary disease.  
Complete response (CR)  â€¢ Complete resolution of lymphomatous enlargement by CT.  
For participants  with a previous positive PET scan, a 
post-treatment residual mass of any size is considered a CR 
as long as it is PET -negative.  
Partial response (PR)  â€¢ > 50% decrease in the sum of the product of the greatest 
perpendicular diameters (SPD) of the mediastinal 
enlargement.  For participant s with a previous positive PET 
scan, post -treatment PET must be positive in â‰¥ 1 previously 
involved site.  
Incyte Corporation  Page 90 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Progressive disease (PD)  â€¢ > 25% increase in the SPD of the mediastinal enlargement.  
For participant s wit h a previous positive PET scan, 
post-treatment PET must be positive in â‰¥ 1 previously 
involved site.  
No response (NR)  â€¢ Failure to qualify for PR or PD . 
Relapse  â€¢ Recurrence of mediastinal enlargement after achieving CR.  
For participant s with a previous positive PET scan, 
post-treatment PET must be positive in â‰¥ 1 previously 
involved site.  
Response Criteria for Minimal Residual Disease  
The optimal sample for MRD assessment is the first pull or early pull of the bone marrow aspirate.  
â€¢ MRD in ALL refers to the presence of leukemic cells below the threshold of detection by 
conventional morphologic methods.  Participants who achieved a CR by morphologic assessment 
alone can potentially harbor a large number of leukemic cells in the bone marrow.  
â€¢ MRD is an essen tial component of participant evaluation over the course of sequential therapy.  If a 
participant is not treated in an academic center, there are commercially available tests available that 
should be used for MRD assessment.  
â€¢ Studies in both children and ad ults with ALL have demonstrated the strong correlation between 
MRD and risks for relapse, as well as the prognostic significance of MRD measurement during and 
after initial induction therapy.  
â€¢ The most frequently employed methods for MRD assessment include 6-color flow cytometry assays, 
specifically designed to detect abnormal MRD immunophenotypes, real -time quantitative 
polymerase chain reaction (RQ -PCR) assays, and next -generation sequencing based assays to detect 
fusion genes, clonal rearrangements in imm unoglobulin (Ig) heavy chain genes, and/or T -cell 
receptor (TCR) genes.  
â€¢ Current 6 -color flow cytometry, or PCR methods can detect leukemic cells at a sensitivity threshold 
of < 1 Ã— 104 (< 0.01%) bone marrow mononuclear cells (MNCs).  The concordance rate f or 
detecting MRD between these methods is generally high.  
âˆ’ Timing of MRD assessment:  
â–ª Upon completion of initial induction.  
â–ª Additional timepoints should be guided by the regimen used.  
Incyte Corporation  Page 91 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  APPENDIX  G. PROTOCOL AMENDMENT S UMMARY OF CHANGES  
Document  Date  
Amendment 1  22 APR 2020  
Amendment 2  14 OCT 2020  
Amendment 3  17 AUG 2021  
Amendment 4  08 DEC 2022  
Amendment 4 ( 08 DEC  2022 ) 
Overall Rationale for the Amendment:  
The primary purpose of the amendment is to clarify the inclusion  criteria for Part 2 (adult 
participants only)  in order to ensure enrollment is consistent with the Yescarta label .  Additional 
changes are summarized below.  
1. Title Page  
Description of change:   The IND n umber  was updated to  
Rationale for change:   To update  the IND number.  
2. Section 1 , Protocol Summary  (Figure 1 :  Study Design Schema Part 1 ; Figure 2:  
Study Design Schema Part 2)  
Description of change:   Updated the  ECOG  performance status scores to be consistent 
with enrollment criteria . 
Rationale for change:   To correct ECOG score in figures to coincide with Criterion 3 . 
3. Section  1, Protocol Summary (Table 3:  Schedule of Activities ) 
Description of cha nge:  Notes  were  added to  FDG -PET CT/MRI , CRS assessments , and 
ICANS assessments.  
Rationale for change:   Clarification.  
  
 
 
 
 
 
 
 
 
 

Incyte Corporation  Page 92 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  5. Section 5.1 , Inclusion Criteria  (Criterion 1)  
Description of change:   Added criteria associated with  participant  age eligibility for 
Part 2 of the study (ie , 18 years of age or older , as opposed to 12 and older in Part 1 ). 
Rationale for change:   Request ed by the IRB to have study treatment guidance 
consisten t with the Yescarta label . 
 
 
 
 
. 
 
 
7.  Section 9.6 , Emergency Unblinding of Treatment Assignment  
Description of change:   Added text for emerg ency unblinding.  
Rationale for change:   Standard  language for emergency unblinding is necessary for 
those participants under study treatment in  Part 2 . 
8. Section 9.10,  Treatment of Overdose  
Description of change:   Changed the definition of overdose from 200 mg QD to 400  mg 
within a 24 -hour period.  
Rationale for change:   To update the dose that denotes  overdose for participants.  
  
 
 
 
10. Incorporation of administrative changes.  Other regulatory guidance and 
administrative changes have been incorporated throughout the Protocol and are noted in 
the redline version of the amendment.  

Incyte Corporation  Page 93 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Amendment 3 ( 17 AUG 2021)  
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to include an additional dosing regimen  (Part  2) of 
itacitinib.  
1. Title page; Section 1, Protocol Summary  
Description o f change:   Removed "Single Arm, Open Label" from the protocol title.  
Rationale for change:   An additional dosing regimen no longer supports the single arm, 
open label title.  
2. Section 1, Protocol Summary (Table 1:   Primary and Major Secondary Objectives 
and Endpoints); Section 3, Objectives and Endpoints  (Table 7:  Objectives and 
Endpoints)  
Description of change s: 
â€¢ Added clarification to the objectives and endpoints for Part 1 and Part 2 to support 
selection of an optimal dose/schedule of itacitinib for subsequent trials.  
â€¢ Modified t he secondary endpoint for ICANS  regardless of CRS, after IEC therapy  to 
include severity of ICANS in order to be consistent with the objective . 
â€¢ Modified t he secondary endpoints for evaluating ICANS and CRS at Day 28 to 
include time to onset  and duration.  
â€¢ Modified t he secondary endpoint for characterizing the safety of itacitinib to include 
the evaluation for ï‚³ Grade 3 cy topenias ongoing by Day 30 . 
â€¢ Moved t he objective and endpoint for evaluating tocilizumab treatment from 
explora tory to secondary and the language was clarified  to assess intervention for CRS 
and ICANS and to include dexamethasone treatment.  
  
 
Rationale for changes:   To provide clarification for the evaluation of CRS and ICANS.  
To ensure the objective and endpoints for evaluating rescue medication is accurate.   
  
3. Section 1, Protocol Summary  (Table 2:  Key Study Design Elements; Figure 1:  
Study Design Schema Part 1; Figure 2:  Study Design Schema Part 2) ; Section 4 .1, 
Overall Design  
Description of change:   Added  clarification  to distinguish Part 1  from Part 2 and added 
language to describe the design for Part 2, which is a randomized portion of the study that 
has been added to evaluate itacitinib 200 mg BID versus placebo.   A study design schema 
for Part 2 was added as Figure 2 . 
Rationale for change:   To describe Part 2 of the study . 

Incyte Corporation  Page 94 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  5. Section 2.2.3 , Itacitinib Clinical Safety Summary  
Description of change:   Updated t he safety summary to includ e information from the 
data cutoff in APR  2021, since the previous information was from DEC  2019.  
Rationale for change:   To include a more recent total of the number of participants who 
have been treated with itacitinib.  
6. Section 2.3.3, Preliminary Results from Part 1  
Description of change:  Added a  new section with the results from the interim a nalysis 
of Part 1 based on the data cutoff (08 JAN 2021).  
Rationale for change:   To provide a summary of preliminary re sults from Part 1 of the 
study.  
7. Section 2.3.4,  Rationale for Part 2  
Description of change:   Added a new section to describe the rational e for Part 2, 
including population PK modeling and itacitinib concentration -time profiles.   Language 
was also included to provide a brief summary of the design for Part 2. 
Rationale for change:   To provide the rationale for evaluating a new dose schedule, 
itacitinib 200  mg BID , and a brief summary of the Part 2 design.  

Incyte Corporation  Page 95 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  8. Section 5.1, Inclusion Criteria  (Criterion #2);  Section 6.2 , Immune Effector Cell 
Therapy  
Description  of change:   Updated i nclusion  criterion  2 to distinguish between Part  1 and 
Part 2.  The eligible participant population for Part 1 was not changed.  The eligible 
participant population for Part 2  includes only those receiving Yescarta  for relapsed or 
refractory large B -cell lymphoma  or follicular lymphoma . 
Rationale for change:   To clarify that the participant population in Part 2 will include 
only those receiving Yescarta.  
9. Section 6 .1, Study Treatment  Administered (Table 9:  Study Treatmen t 
Information)  
Description of change:   Added s tudy treatment (itacitinib or placebo)  and dose strength 
for Part 2.  
Rationale for change:   To add the study treatment for Part 2 . 
10. Section 6.1.3, Dose Modifications for Itacitinib ; Section 6.4.2, Restricted 
Med ications and Procedures  
Description of change:   Added Part 2 treatment regimen and to  indicate that if a dose 
reduction is required, participants may tak e 1 tablet instead of 2 (reduced to 100 mg BID 
or placebo).  
Rationale for change:   To provide dose modi fication guidance for participants in Part 2 . 
11. Section 6.3, Measures to Minimize Bias :  Randomization and Blinding  
Description of change:   Added  that Part 2 participants will be randomized to receive 
either itacitinib 200mg BID or placebo.  Investigators and participants will be blinded.  
Rationale for change:   To clarify randomization and blinding for Part 2 . 
12. Section 6.4.2, Restricted Medications and Procedures ; Section 6.4.3 , Prohibited 
Medications and Procedures  
Description of change:   Moved l anguage regarding rescue medication with  Tocilizumab 
and/or corticosteroids for CRS Grade 1 from the prohibited medications to restricted 
medications  and procedures . 
Rationale for change:   To provide guidance for when rescue medication is needed for 
CRS.  
 
 
 
 
 
 

Incyte Corporation  Page 96 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  14. Section 9.4, Reporting of Serious Adverse Events  
Description of change:   Update d to clarify  that the investigator must report SAEs within 
24 hours of learning of its occurrence , and removed the guidance with regard to faxi ng 
SAE reports . 
Rationale for change:   To be compliant with current guidance  from Incyte 
Pharmacovigilance.  
15. Section 10 .1, Sample Size Determination  
Description of change :  Added a  sample size determination for P art 2 using a Bayesian 
approach, and added Table 19 to describe Bayesian posterior probability scenarios and 
provide rationale.  
Rationale for change:   To support the additional analyses that will be conducted for 
Part 2.  
16. Section 10.3, Level of Significance  
Description of change:   Modified the l evel of significance to include language for 
Part 2. 
Rationale for change:   To support the additional analys es that will be conducted for 
Part 2. 
17. Section 10.4.1.2, C ytokine Release Syndrome  Rate by Day 14 â€“ Part 2  
Description of change:   Added a new se ction to describe  the primary, secondary, and 
safety analys es for Part 2.  
Rationale for change:  To support the additional analys es that will be conducted for 
Part 2. 
18. Section 10.4.2.1, Part 2  Analysis  
Description of change:   Added a new section to  provide detail on  treatment group 
comparisons . 
Rationale for change:   To support the additional analys es that will be conducted for 
Part 2. 
19. Section 10.4.3, Safety Analyses  
Description of change:   Updated to clarify that safety summaries will be presented by 
the 2 dose grou ps and placebo for all safety endpoints.  
Rationale for change:   To support the additional analyses that will be conducted for 
Part 2. 
20. Section 10.5, Interim Analysis  
Description of change:   Updated to clarify that no interim analysis is planned for Part  2. 
Rationale for change:   To clarify that an interim analysis will not  be conducted for 
Part 2. 
Incyte Corporation  Page 97 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  21. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version o f the 
amendment.  
Incyte Corporation  Page 98 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Amendment 2 ( 14 OCT 2020 ) 
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to revise inclusion criterion 2, in order to allow for the 
use of any IEC therapy that is approved by the health authority in the country where the study is 
being conducted.  
1. Section 1, Protocol Summary (Table 2:  Key Study Design Elements; Treatment 
Groups and Duration);  Section 4.1, Overall Design; Section  5.1, Inclusion Criteria; 
Section 6.2, Immune Effector Cell Therapy; Section  10.4, Statistical Analyses ; 
Section 10.4.1.1, CRS Rate by Day 14; Section  10.4.2.1, ICANS Incidence; 
Section  10.4.3, Safety Analyses ; Section  10.5, Interim Analysis  
Description of change:   Revised to allow IEC the rapy that is approved by the health 
authority in the country where the study is being conducted.  
Rationale for change:   To allow additional  options for  IEC therapy.  
2. Section 2.1, Background; Section 2.4 Benefit/Risk Assessment  
Description of change:   Revi sed to include information regarding brexucabtagene 
autoleucel, a new FDA approved IEC therapy for MCL.   
Rationale for change:   To include new information regarding IEC therapy.  
3. Section 5.2 , Exclusion Criteria (Table 8:  Exclusionary Laboratory Values)  
Description of change:   Corrected t he unit for hemoglobin to g/dL . 
Rationale for change:   To correct the unit  typo for hemoglobin . 
4. Section 6.4.3, Prohibited Medications and Procedures  
Description of change:   Added that participants who are administered tocilizumab 
should be discontinued from study treatment.  
Rationale for change:   To provide clarification with regard to use of tocilizumab.  
  
 
 
 
 
6. Section 9.4, Reporting of Serious Adverse Events  
Description of change:   Added cl arification that if an SAE occurs more than 30 days 
after the last dose of study treatment, it is only required to be reported if it is considered 
to be related to itacitinib . 
Rationale for change:   To provide clarification with regard to SAE reporting.  

Incyte Corporation  Page 99 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  Amendment 1 (22 APR 2020)  
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to clarify study procedures and provide more current 
information in response from sites and ethics committees.  
Additional changes from Administrative Cha nge 1 were also included . 
1. Section 1, Protocol Summary ( Table 3 :  Schedule of Activities ); Section 5.2, 
Exclusion Criteria ( Table 8 :  Exclusionary Laboratory Values ); Section 8.9.3 , 
Electrocardiograms and Echocardiogram s 
Description of change:   Echocardiogram was added as a screening assessment.  
An assessment of LVEF will be performed locally by  ECHO or multigated analysis to 
determine the cardiac function of the participant  and to confirm study eligibility.  If 
cardiac functional status is obtai ned within 60 days of the screening visit, for the 
purposes of IEC therapy, that result may be used for this study.  
Rationale for change:   This assessment was inadvertently left out of the original 
Protocol .  The cardiopulmonary exclusion for LVEF  should b e confirmed by an ECHO.  
2. Section 1, Protocol Summary (Table 3:  Schedule of Activities); Section 8.3.2,  
Physical Examinations; Section 8.3.3, Vital Signs and Temperature Monitoring  
Description of change:   Height should be assessed at screening only.  Weigh t will be 
assessed at each visit where vital signs are assessed.  Temperature monitoring will being 
on Day âˆ’3.   Additionally, the participant will be encouraged to use a TempTraq device as 
a tool for temperature monitoring.  Additional instructions regardi ng the TempTraq 
device will be provided separately.  If a participant in unable to wear the device at any 
point during the treatment period, this will not be considered a Protocol deviation.  
Rationale for change:   To add a height assessment to the Protocol , to update the timing 
for weight assessments, and to clarify guidance and encourage the use of a tool that will 
provide consistency with regard to temperature monitoring.  The temperature monitoring 
time frame will be consistent with the start and stop of  study treatment and will begin 
3 days before  IEC in order to capture the participant 's baseline temperature.  
  
 
 
 
 

Incyte Corporation  Page 100 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL    
 
 
 
 
 
 
5. Section 2.2.1, Nonclinical Drug Metabolism and Pharmacokinetics  
Description of change:   The heading  was updated to clarify that this section only  
contains  nonclinical information.  Language was added to summarize the nonclinical 
data, including in vitro study results.   Previous information that is no longer relevant was 
removed.  
Rationale for change:   Response to ethics committees . 
6. Section 2.2.2, Clinical Drug Metabolism and Pharmacokinetics  
Description of change:   Section added to summarize the clinical PK data that are 
available.  
Description of change:   This information was inadvertently left out of the original 
Protocol.  
7. Section 2.2.3 , Itacitinib Clinical Safety Summary  
Description of change:   The section was updated based on the most current IB, with a 
data cutoff date  of 13 DEC 2019.  The number of participants and number of clinical 
studies have increased.  
Rationale for change:   To provide current information.  
8. Section 2.3.2 , Justification for Dose  
Description of change:   A clarification was made with regard to the sum mary of  the 
acute GVHD pilot study comparing 200 mg QD with 300 mg QD.  
Rationale for change:   To provide more accurate information . 
9. Section 6.4.2, Restr icted Medication and Procedures  
Description of change:   The following were removed :  "No dose adjustment  is 
recommended for concomitant administration of other less strong CYP3A inhibitors ," 
and, "If administration of corticosteroids is required, the sponsor medical monitor should 
be consulted ." 
Rationale for change:   To provide more accurate guidance with r egard to restricted 
medication.  
10. Section 6.4.2 , Prohibited Medications and Proced ures 
Description of change:   The fourth bullet was revised to include corticosteroids.  
Rational for change:  To clarify that corticosteroids for Grade 1 CRS are prohibited.  

Incyte Corporation  Page 101 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  11. Section 8.1.2 , Screening Procedures  
Description of change:  The following sentence was removed , "Screening may not 
exceed 7 days. " 
Rational for change:   To allow for flexibility in screening procedures that may be 
conducted prior to the screening period . 
12. Section 8.1.3 , Interactiv e Response Technology Procedure  
Description of change:  Clarification added in regard to when IRT should be called.  
Rational for change:   To provide guidance with regard to IRT procedures.  
13. Section 8.2.2 , ICANS Status  
Description of change:  The following sentence was added , "If the participant has no 
impairment (ICE score of 10), then Grade 0 may be entered in the EDC for ICANS 
Grade. " 
Rational for change:  To provide guidance with regard to ICANS grading.  
14. Section 8.4 , Hematologic Di sease Status  
Description of changes:  
â€¢ Clarification regarding standard of care was added.  
â€¢ The following sentence was removed , "Only the response result and the date the 
assessment was performed will be captured in the eCRF. " 
â€¢ The following sentence was added  "A bone marrow assessment performed within 
180 days of Day âˆ’3 can be used for the purpose of this study. " 
Rational for change:   To clarify procedures and add flexibility.  
 
 
  
 
  
 
  
. 
16. Section 8.9.3, Electrocardiograms and  Echocardiograms  
Description of change:   QT was added to  the text for ECG measurements.  
Rationale for change:   QT should be assessed.  

Incyte Corporation  Page 102 of 102 
Protocol INCB 39110 -211 Am  4 Version 5 08 DEC  2022  
VV-CLIN -001046   CONFIDENTIAL  17. Section 10.5 , Interim Analysis  
Description of changes:  Text was added to indicate t he results from the interim analysis 
will be reviewed by the DSMB ,  
 
Rationale for Change :  Based on feedback from ethics committee.  
18. Appendix C , Instruction to Participants for Handling Itacitinib  
Descriptio n of change:   The last bullet was revised; if an itacitinib dose is missed by 
more than 8 hours , that dose should be skipped and the next scheduled dose should be 
administered at the usual time.  
Rationale for change:   The previous language indicated 4 hours, which is incorrect.  
19. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  

Signature Page for VV-CLIN-001046 v5.0
Signature Page for VV-CLIN-001046 v5.0Approval Task
08-Dec-2022 13:16:33 GMT+0000
Approval Task
08-Dec-2022 16:06:53 GMT+0000
Approval Task
08-Dec-2022 16:22:36 GMT+0000
Approval Task
08-Dec-2022 16:56:16 GMT+0000
